

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement

Albert Wiegman, Mafalda Bourbon, Tomas Freiburger, Samuel S Gidding, Susanne Greber-Platzer, Urh Groselj, Kirsten B Holven, Lisa C Hudgins, Steve E Humphries, Barbara A Hutten, Daiana Ibarretxe, Cristina Pederiva, Noel Peretti, Frederick J Raal, Uma Ramaswami, Veronika Sanin, Raul D Santos, Elisabeth Steinhagen-Thiessen, Gerald F Watts, Rosie Perkins, Marianne Benn, Christoph J Binder, Stefano Romeo, Jeanine E Roeters van Lennep

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement

Albert Wiegman ^{1,2,3,*}, Mafalda Bourbon ^{4,5}, Tomas Freiburger ⁶, Samuel S. Gidding ⁷, Susanne Greber-Platzer ⁸, Urh Groselj ^{9,10}, Kirsten B. Holven ^{11,12}, Lisa C. Hudgins ¹³, Steve E. Humphries¹⁴, Barbara A. Hutten ^{2,3,15}, Daiana Ibarretxe ¹⁶, Cristina Pederiva ¹⁷, Noel Peretti ^{18,19}, Frederick J. Raal ²⁰, Uma Ramaswami²¹, Veronika Sanin ²², Raul D. Santos²³, Elisabeth Steinhagen-Thiessen^{24,25}, Gerald F. Watts ^{26,27}, Rosie Perkins ²⁸, Marianne Benn ^{29,30}, Christoph J. Binder ³¹, Stefano Romeo ^{28,32,33,34,35}, and Jeanine E. Roeters van Lennep ^{36,*†}

¹Department of Paediatrics, Amsterdam University Medical Center, Location AMC, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; ²Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; ³Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam UMC, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; ⁴Unidade de Investigação e Desenvolvimento, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal; ⁵Centro Cardiovascular Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; ⁶Centre of Cardiovascular Surgery and Transplantation Brno, and Medical Faculty, Masaryk University, Brno, Czech Republic; ⁷Department of Genomic Health, Geisinger, Danville, PA, USA; ⁸Department of Pediatrics and Adolescent Medicine, Division of Pediatric Pulmonology, Allergology and Endocrinology, Medical University of Vienna, Vienna, Austria; ⁹Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; ¹⁰Department of Endocrinology, Diabetes, and Metabolic Diseases, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia; ¹¹Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; ¹²Norwegian National Network on Familial Hypercholesterolemia, Oslo University Hospital, Oslo, Norway; ¹³Department of Pediatric Cardiology, Weill Cornell Medical College, New York, NY, USA; ¹⁴Institute of Cardiovascular Science, Faculty of Population Health, University College London, London, UK; ¹⁵Department of Epidemiology and Data Science, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; ¹⁶Unitat de Medicina Vascular i Metabolisme, Hospital Universitari Sant Joan, IISPV, CIBERDEM, Universitat Rovira i Virgili, Reus, Spain; ¹⁷Paediatrics Unit, Clinical Service for Dyslipidaemias, Study and Prevention of Atherosclerosis in Childhood, ASST-Santi Paolo e Carlo, Milan, Italy; ¹⁸CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon, Lyon, France; ¹⁹Department of Pediatric Gastroenterology-Hepatology and Nutrition, Hôpital Femme Mere Enfant HFME, Hospices Civils de Lyon HCL, Bron, France; ²⁰Carbohydrate and Lipid Metabolism Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ²¹Royal Free London NHS Foundation Trust, University College London, London, UK; ²²Department of Cardiology, Deutsches Herzzentrum München, Klinikum der Technischen, Universität München, Munich, Germany; ²³Academic Research Organization, Hospital Israelita Albert Einstein and Lipid Clinic Heart Institute (InCor), University of São Paulo, São Paulo, Brazil; ²⁴Lipid Clinic at the Interdisciplinary Metabolism Center, Charité-University Medicine Berlin, Berlin, Germany; ²⁵Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Rostock, Rostock, Germany; ²⁶School of Medicine, University of Western Australia, Perth, Australia; ²⁷Department of Cardiology, Royal Perth Hospital, Western Australia, Australia; ²⁸Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; ²⁹Department of Clinical Biochemistry, Copenhagen University Hospital-Rigshospitalet, Centre of Diagnostic Investigation, Copenhagen, Denmark; ³⁰Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; ³¹Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; ³²Department of Medicine (H7), Karolinska Institute, Huddinge, Stockholm, Sweden; ³³Department of Endocrinology, Karolinska University Hospital, Huddinge, Stockholm, Sweden; ³⁴Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; ³⁵Clinical Nutrition Unit, Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy; and ³⁶Department of Internal Medicine, Cardiovascular Institute, Erasmus Medical Center, Dr Molewaterplein 40, Rotterdam 3015 GD, The Netherlands

Online publish-ahead-of-print 25 May 2026

* Corresponding authors: Tel: +31630132065, Email: a.wiegman@amsterdamumc.nl (A.W.); Tel: +31652313132, Email: j.roetersvanlennep@erasmusmc.nl (J.R.v.L.)

† For list of other contributors, see [Appendix](#).


© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Abstract

Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated LDL cholesterol (LDL-C) concentrations. FH exists in two forms: heterozygous FH (HeFH), which affects around 1 in 300 people worldwide, and homozygous FH (HoFH), which affects around 1 in 300 000. Individuals with FH are at increased risk of premature atherosclerotic cardiovascular disease (ASCVD) and death, and those with HoFH are, if untreated, at extreme risk of ASCVD manifestations even before adulthood. Early diagnosis and treatment in childhood can extend or normalize life expectancy, but limited awareness, underdiagnosis, and undertreatment remain major challenges. This consensus statement aims to address these challenges, supported by increased knowledge of the pathogenesis of FH and the availability of an increasing range of lipid-lowering therapies (LLTs) that can be used from early ages. To increase the detection rate of FH, all countries are encouraged to establish a paediatric screening programme and, given that current diagnostic criteria often fail to identify children with an FH-causing genetic variant, revised diagnostic criteria are presented. Updated LDL-C treatment goals are proposed, and the importance of starting LLTs before puberty in children with HeFH, and, if needed, from 6 years, is highlighted. Guidance on how to manage FH is provided, including treatment algorithms for use in children with either HeFH or HoFH and a discussion on how to promote a smooth transition to adult care. Early detection and optimal treatment as advocated in this consensus statement are crucial to improving life expectancy for children and adolescents with FH.

Graphical Abstract



Individuals with untreated heterozygous familial hypercholesterolaemia (HeFH) or homozygous familial hypercholesterolaemia (HoFH) have high or extremely high LDL cholesterol (LDL-C) concentrations and are at increased risk of premature atherosclerotic cardiovascular disease. Lipid-lowering therapies reduce the cumulative LDL-C exposure and slow the progression of atherosclerosis.

For HeFH, diagnosis (by lipid and/or genetic testing) should occur between 1 and 10 years, and management (lifestyle advice and pharmaceutical treatment) should start from 6 years and by no later than 10 years. The LDL-C treatment goal is 3.5 mmol/L from 6 to <10 years and 3.0 mmol/L from 10 to <18 years or from 6 years if major risk enhancers are present. Children with familial hypercholesterolaemia (FH) should be given knowledge about their condition and management from 10 years at the latest to improve long-term adherence to clinical management. From the age of 16 years, adolescents with FH and major risk enhancers present should start moving towards lower LDL-C treatment goals to bridge the gap to recommended levels for adults with FH and another major risk factor.

Keywords

Familial hypercholesterolaemia • Children • Adolescents • Lipid-lowering therapy • Cumulative low-density lipoprotein cholesterol exposure • Cardiovascular risk

Introduction

Heterozygous familial hypercholesterolaemia (HeFH) is one of the most frequent monogenic disorders, affecting ~1 in 300 people worldwide.^{1,2} Heterozygous familial hypercholesterolaemia is characterized by elevated concentrations of LDL cholesterol (LDL-C) that if untreated, or undertreated, result in an increased risk of premature atherosclerotic cardiovascular disease (ASCVD).^{3,4} Homozygous familial hypercholesterolaemia (HoFH) is rare with an estimated global prevalence ranging between 1 in 250 000 and 1 in 360 000.^{1,2} Individuals with HoFH may have extremely high LDL-C concentrations and are at very high risk of coronary and aortic stenosis and even death in childhood or adolescence if untreated.⁵

Underdiagnosis remains a major issue. Familial hypercholesterolaemia (FH) affects around 500 000 children in Europe,^{1,2} but <10% of these children are identified.⁶ The European Atherosclerosis Society (EAS) Familial Hypercholesterolaemia Studies Collaboration, which included over 42 000 adults from 56 countries, showed that the median age for diagnosis of FH is 44 years; of note, only 2% of the adults included were diagnosed before the age of 18 years.⁷ Family cascade or universal screening programmes (using genetic and/or lipid tests) have been shown to increase the detection rate, but these are not widespread globally. Even if diagnosed, many children with FH are not adequately treated throughout childhood and adolescence.^{8,9} Functional and morphological changes in the arterial wall, indicative of the early stages of atherosclerosis, have been observed in children with FH, even before adolescence.^{10–13} Therefore, diagnosis in the first decade of life and appropriate treatment of FH in children is essential. Strategies are thus required to increase awareness of FH and to emphasize the importance of treating a disorder in childhood that is unlikely to present cardiovascular symptoms until later in life.

In the decade since the 2015 EAS consensus statement on FH in children,⁴ our knowledge of the pathogenesis of FH has increased markedly, and clinicians now have access to a wider range of lipid-lowering therapies (LLTs). In this current EAS consensus statement, we present revised diagnostic criteria, the current screening options, proposals for lower LDL-C treatment goals, and revised treatment algorithms, with a focus on HeFH. In addition, we provide updates on the information presented in the 2023 EAS consensus statement on HoFH,⁵ in particular on the LLTs that are approved for children with HoFH. We also outline how to manage FH in children and adolescents in the context of the newly available treatments. Finally, we discuss how to manage the transition to adult care and implementation

strategies. [Box 1](#) summarizes the updated information included in this current EAS consensus statement.

Diagnosis of familial hypercholesterolaemia


Diagnostic criteria and tools

The 2015 EAS consensus statement on FH in children proposed that any child with an LDL-C ≥ 5.0 mmol/L (190 mg/dL) measured twice after dietary intervention has a high probability of genetically based FH; this threshold was lowered to ≥ 4.0 mmol/L (155 mg/dL) if there was a family history of premature ASCVD and/or high baseline cholesterol in one parent, and further lowered to LDL-C ≥ 3.5 mmol/L (135 mg/dL) if one parent had a genetic diagnosis of FH.⁴ However, a recent study showed that although high specificity is achieved when using these criteria, early diagnosis in almost half of children with an FH-causing variant would have been missed.¹⁴

To improve diagnostic sensitivity, here we propose a modification of these criteria, as shown in [Figure 1](#) for the different entry points for a child suspected to have FH. A child should be referred to a healthcare professional with experience in managing children with FH for further testing according to the following scenarios: When the child has (1) a parent with a known pathogenic FH variant regardless of the LDL-C value of the child (cascade screening); (2a) LDL-C >4.5 mmol/L (175 mg/dL) identified either from inclusion in a universal FH

Box 1 What is new in this European Atherosclerosis Society consensus statement on children with familial hypercholesterolaemia?

- Updated diagnostic criteria to improve diagnostic sensitivity.
- Proposed lower age to start treatment.
- Proposed lower LDL-C treatment goals, made possible by the availability of new LLTs.
- Emphasis on the importance of reducing cumulative LDL-C exposure.
- Updated treatment algorithms and the latest evidence supporting the use of novel LLTs.
- Proposals to facilitate improved transition to adult care and implementation strategies.



In Scenario 1 in [Figure 1](#), a child with a positive test for an FH-causing variant (and therefore 'definite FH') should be referred to clinical management of FH if LDL-C is >3.5 mmol/L (135 mg/dL) when aged below 10 years or >3.0 mmol/L (115 mg/dL) when aged 10 years and above if other major risk enhancers are present (see footnote in [Table 1](#)). If a parent has a genetic diagnosis but the child does not undergo genetic testing (because it is not available or the parents do not consent), then the child should be considered to have 'clinical FH' if LDL-C

In children with a clinical diagnosis of FH but no known FH-causing variant, one in three have high concentrations of lipoprotein(a) [Lp(a)].^{18,19} We therefore propose that a test for Lp(a) is performed in all children with suspected FH at the same time as paediatric screening (but not before 5 years of age). Genetic association and Mendelian randomization studies support a causal relationship between elevated Lp(a) and risk of ASCVD.²⁰ We therefore also encourage cascade testing of

Table 1 Comparison of the diagnostic criteria and LDL cholesterol treatment goals proposed in the current consensus and in the 2015 European Atherosclerosis Society consensus statement⁴ for children with familial hypercholesterolaemia

2015	2026
Diagnostic criteria	
Highly probable FH	Clinical FH
- LDL-C ≥5.0 mmol/L (190 mg/dL) measured twice after dietary intervention - LDL-C ≥4.0 mmol/L (155 mg/dL) if family history of premature ASCVD and/or high baseline cholesterol in one parent - LDL-C ≥3.5 mmol/L (135 mg/dL) if one parent has a genetic diagnosis of FH	- LDL-C >4.5 mmol/L (175 mg/dL) - LDL-C >3.5 mmol/L (135 mg/dL) if family history of premature ASCVD and/or high baseline cholesterol in one parent - LDL-C >3.0 mmol/L (115 mg/dL) if one parent has a genetic diagnosis of FH
Definite FH	Definite FH
If a child has a genetic diagnosis of FH	If a child has a genetic diagnosis of FH
LDL-C treatment goals	
Start pharmacological treatment at 8 years	Start pharmacological treatment ideally at 6 years
Reduce LDL-C concentration	Reduce LDL-C concentration
- by 50% from baseline at 8–10 years - to 3.5 mmol/L (135 mg/dL) at >10–<18 years	- to ≤3.5 mmol/L (135 mg/dL) at 6–<10 years - to ≤3.0 mmol/L (115 mg/dL) at 10–<18 years or with other major risk enhancers^a at 6–<10 years

ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolaemia; LDL-C, LDL cholesterol.
^aMajor risk enhancers: lipoprotein(a) ≥250 nmol/L (120 mg/dL)—a high concentration associated with a doubled risk of ASCVD in the adult population^{15,16}; diabetes; hypertension; chronic inflammatory diseases; chronic kidney disease; Kawasaki disease; human immunodeficiency virus; cancer survivor (discussed in Clinical Management of Heterozygous Familial Hypercholesterolaemia).

Box 2 Advantages and disadvantages of genetic testing for familial hypercholesterolaemia

Advantages of a confirmed genetic diagnosis of FH

Confirms definitive FH and establishes the FH diagnosis unequivocally.
Supports the clinician when deciding which LLT to use.
Helps the parents decide whether and when their child should start LLT.³⁶
Enables access to special therapies.
Prompts testing of parents and siblings who are at 50% risk of carrying the FH-causing variant.
Encourages cascade testing in the extended family.
Creates awareness that FH is passed on to the next generation.
Encourages adherence to LLT.³⁷
Encourages adherence to a healthy lifestyle³⁸ and not smoking/vaping.
Creates awareness that atherosclerosis starts at birth.³⁹

Disadvantages

Potential confusion of diagnosis if a variant of uncertain significance is found.
Life and health insurance issues in some countries.
Potential stigmatization.
Psychological distress for individuals and their family.

the parents and grandparents of a child found to have elevated Lp(a) [>105 nmol/L (50 mg/dL)]¹⁵ to identify those at increased cardiovascular risk and who would benefit from immediate treatment.

Tools to improve the accuracy of diagnosing FH have been developed in adults and include the Simon Broome,²¹ Dutch Lipid Clinic Network (DLCN),²² and Make Early Diagnoses to Prevent Early Deaths²³ criteria. However, these scoring systems fail to sufficiently identify children with FH.¹⁴ A new scoring system, termed the Familial Hypercholesterolaemia Paediatric Diagnostic Score (FH-PeDS), has recently been designed specifically in children using data from a universal screening cohort from Slovenia and validated using data from the Portuguese FH study.²⁴ This score has been shown to diagnose children with genetically confirmed FH more accurately compared with the DLCN or Simon Broome criteria (for details, see [Supplementary data online, Table S1](#))²⁴ and could be a useful tool in the future to stratify children with suspected FH for genetic testing. A machine-learning version of FH-PeDS is also available as an on-line tool.²⁴ However, validation of FH-PeDS and the machine-learning version is required in multiple other cohorts that include genetic testing²⁵ and individuals of different genetic ancestry.

Genetic testing

We propose that any child with suspected FH as shown in [Figure 1](#) should be offered genetic testing to confirm his/her

diagnosis.^{4,26} The FH-causing genes are *LDLR*, *APOB*, and *PCSK9*. Some laboratories still use Sanger sequencing and Multiplex Ligation-dependent Probe Amplification approaches to identify FH gene variants, mainly in *LDLR*, or Sanger sequencing alone to study *PCSK9* and exon 26 and 29 of *APOB*. Today, however, with the use of next-generation sequencing (NGS), it is possible to sequence completely *LDLR*, *APOB*, and *PCSK9* and to detect large rearrangements in one run. As proposed by an expert panel on genetic testing for FH,²⁷ the genetic test for FH should ideally be performed by a NGS panel of eight genes: the three FH-causing genes noted above, the less common FH-associated genes *APOE* and *LDLRAP1*, and the three phenocopy genes (*ABCG5*, *ABCG8*, and *LIPA*). Rigorous criteria have been developed to guide laboratories in *LDLR* variant classification,²⁸ which are universally accepted and should be used by all labs performing genetic testing for FH. The only known FH-causing variant in *APOE* is p.Leu167del,²⁹ and biallelic pathogenic variants in *LDLRAP1* alleles cause autosomal recessive hypercholesterolaemia. Biallelic pathogenic variants in *ABCG5* and *ABCG8* cause sitosterolaemia, a recessive disease, which results in accumulation of plant sterols and their corresponding saturated stanols in the body. Clinical features include xanthomas, premature atherosclerosis, and thrombocytopenia.³⁰ Biallelic pathogenic variants in *LIPA* cause lysosomal acid lipase deficiency (LALD), which is also recessive. Clinical features include liver disease (ranging from steatosis to cirrhosis) and severe dyslipidaemia.³¹

If a child has low LDL-C despite a pathogenic FH variant, consider testing for primary hypocholesterolaemia, which is caused by pathogenic variants in genes for lipoprotein assembly or secretion [*MTTP* and *SAR1B* (both recessive), and *APOB* (dominant)] or for enhanced lipoprotein catabolism [*ANGPTL3* and *PCSK9* loss of function (both dominant)].^{32–34} These variants can mask FH by 'normalizing' LDL-C concentrations in an individual with an FH-causing variant, and the variants that modify lipoprotein assembly and secretion can cause malabsorption and steatosis despite reducing cardiovascular risk.³¹ Such masking of FH can preclude the detection of FH in family members who lack the cholesterol-lowering variant and therefore have elevated cardiovascular risk.

When the family FH variant is known (from an index family member who previously underwent a genetic test), a full genetic study is not required, and a much cheaper and quicker confirmatory test for the family variant can be carried out. This can also be performed using cord blood at birth or a saliva or buccal swab sample, which is easier to obtain than a blood sample from a young child.

Clear advantages and potential disadvantages of genetic testing are listed in Box 2.⁴⁰ A genetic diagnosis gives a clear rationale to parents when considering whether and when their child should start LLT. Where the child is the index case for the family, first-degree relatives, who are at 50% risk of also carrying the FH-causing variant, are then encouraged to be tested. The identification of their FH parent and their subsequent treatment with LLT is of considerable benefit to the child who then has a much greater chance of growing up with two healthy ASCVD-free parents. Several studies have shown that the death of a parent during childhood is associated with lower achievement in school, and poorer mental health.^{41,42} One possible disadvantage of genetic testing is that the parents might feel guilt for passing on the genetic variant to their child. However, genetic counsellors are skilled in

explaining that inheritance of the FH-causing variant is random and that their identified child can now be considered for early preventative treatment to lower their future cardiovascular risk.

In the setting of a negative genetic test for FH and high LDL-C, polygenic risk scores (PRS) based on 12 common LDL-C-raising alleles have been developed⁴³ and validated⁴⁴ to identify individuals with a polygenic cause for their high LDL-C. The finding of a high score (e.g. above the 80th percentile) provides an explanation for severe hypercholesterolaemia in the absence of an FH-causing variant, which has been found to be useful for clinicians and patients.⁴⁵ In adults, these PRS have been shown to considerably increase the diagnostic rate (i.e. the proportion of individuals for whom a genetic cause of their high cholesterol can be given).⁴⁵ However, evidence to demonstrate the benefit of PRS in children is not yet available.

Genetic counselling

Genetic testing should be preceded by genetic counselling. Diagnostic genetic testing of a child or adolescent with suspected FH should ideally be requested by a clinician with skills in counselling, genetics, and care of families with FH. Cascade genetic testing of children and adolescents should be based on shared decision-making and fully informed agreement given by the custodial parent or guardian, with results communicated in a timely manner.⁴⁶ Informed consent by the parent or guardian (or the child themselves depending on their age and the legal age of consent in each particular country) and notification of genetic results should account for literacy and level of comprehension, socio-cultural and psychological background, with full discussion of the possible impact of either a positive or negative result.

Counselling should explicitly communicate the well-established benefits of early diagnosis and timely LLT in FH so that families can make fully informed decisions about cascade testing and appreciate its role in preventing avoidable ASCVD in relatives.

While all children and their families with high LDL-C concentrations and a known pathogenic variant for FH would benefit from genetic counselling, it is especially useful for the children who instead have (i) hypercholesterolaemia with a variant of uncertain significance or a benign variant, (ii) no detectable pathogenic variant but likely to have a polygenic cause of their hypercholesterolaemia, or (iii) cholesterol concentrations within the normal range but in whom a pathogenic variant has been detected.²⁷ Pre-conception genetic counselling is of major importance if both parents have a known pathogenic FH variant.

How to increase the detection rate of familial hypercholesterolaemia in children

It is imperative to increase the detection rate of FH and to diagnose at younger ages to minimize the lifelong exposure to high LDL-C concentrations and reduce the risk of premature ASCVD in the affected individuals (both children and their family members). We therefore encourage every country to establish a (population-based) paediatric FH screening programme, which is in full accordance with the European Commission's recently announced cardiovascular health plan, the Safe Hearts Plan.⁴⁷ The optimal programme for each country (including the specific

age for screening) depends on the healthcare resources, the insurance system, and other country-specific conditions such as geography, infrastructure, population density, social background, and cultural issues.

The ideal age for diagnosis of HoFH is at birth because management should start as early as possible to reduce the particularly high cumulative LDL-C burden. It is less necessary to diagnose HeFH at birth because management does not need to start as early as for HoFH. However, we propose that a diagnosis is made in the first decade of life because (i) children are more likely to adopt and maintain a healthy lifestyle (including eating a healthy diet, exercising, and not starting to smoke or vape) and adhere to drug treatment if encouraged to do so from an early age^{48–50}; (ii) it will lead, through cascade testing of first-degree relatives, to earlier identification of FH in relatives who are unaware of their cardiovascular risk; (iii) screening can be combined with other routine health visits; and (iv) when using cholesterol as the initial measure to diagnose FH, screening performance is optimal between the ages 1 and 9 years, and considerably lower in adolescents and young adults.⁵¹

Paediatric familial hypercholesterolaemia screening programmes

Paediatric FH screening programmes use one or more of the following strategies: cascade screening, where relatives of an individual diagnosed with a genetically confirmed FH variant (index case) undergo genetic testing for this specific variant; universal screening, where all children at a pre-defined age undergo blood lipid screening (and preferably subsequent genetic testing in those with high LDL-C), regardless of other risk factors; opportunistic testing, where tests are offered to children and adolescents who present to healthcare for other reasons (e.g. they have diabetes); and selective screening, where high-risk groups (e.g. with parents or grandparents with premature ASCVD) are targeted for testing.^{8,52–55}

The Netherlands, which was the first country to launch a national screening programme for FH, uses cascade screening.⁵² This approach proved to be both cost-effective from a healthcare perspective and cost-saving from a societal perspective, with a more than 8 euro return on every euro invested.⁵⁶ Similar programmes have been established in other countries, including Norway and the Czech Republic,^{55,57} and its success is recognized worldwide. In Slovenia, the first country to establish a universal screening programme for FH, total cholesterol is measured in all children at the age of 5–6 years followed by genetic testing in those considered at risk and cascade testing of parents and siblings of a child diagnosed with FH.^{58,59} Universal screening has been introduced elsewhere in Europe (e.g. in Bavaria, Germany, reported in the VRONI study⁶⁰). Although universal screening has been shown to be cost-effective in some countries (e.g. in the UK⁶¹ and Argentina⁶²), a recent study found that universal screening was not cost-effective in the USA,⁶³ suggesting that cost-effectiveness is influenced by country-specific healthcare systems. Opportunistic testing combined with cascade screening has been introduced in Lithuania.⁵⁵ Selective screening combined with cascade screening has been used in Italy^{64,65} and Portugal.^{55,66} In the UK, approaches for universal screening at the age of 12 months have been trialled,⁶⁷ but are not yet approved for national roll-out;

cascade testing of children from adult probands is, however, in use.⁶⁸

Barriers and facilitators of screening for FH have been described in detail recently.^{40,69} In 2022, the FH European Community published a call for action in the Prague Declaration to encourage all European countries to adopt FH paediatric screening as part of European and national strategies to prevent premature ASCVD and to promote cardiovascular health.⁷⁰ International networks to promote models for FH diagnosis, screening, and treatment across different countries have been compared.⁷¹

Newborn screening

Newborn screening programmes to detect rare but treatable diseases are established in most countries and achieve near-universal coverage at birth ($\geq 99.9\%$).⁷² Inclusion of FH in a newborn screening programme could offer a unique opportunity for early detection of FH, and would be particularly useful for children with HoFH, allowing them to be diagnosed and treated as early as possible. Identifying a neonate with FH could also lead to the detection, through cascade testing, of FH in a parent and other family members in whom treatment can be started immediately. However, there are several challenges that need to be overcome before this approach can be recommended.

Ongoing studies are investigating which clinical variable would most accurately predict FH in newborns using venous cord blood and dried blood spots.^{73–76} In the first year of life, total cholesterol and LDL-C concentrations increase and show high variability^{77–79} (see [Supplementary data online, Figure S1](#)). Although LDL-C concentrations above the 80th percentile at birth are associated with significantly higher LDL-C concentrations at 14–16 months,⁷⁹ they have not yet proven reliable enough to be used for the diagnosis of FH in newborns.⁸⁰

Pilot studies have shown that genetic testing can detect FH in newborns.⁸¹ However, genetic testing will also identify babies who have variants of uncertain significance or variants with mild phenotypes, leading to complexities in treatment recommendations and unnecessary worry in some cases. Both underdiagnosis and overdiagnosis are potential issues, and robust systems would need to be established for timely recall and confirmatory diagnostics. More reliable tools are needed to promote newborn screening in the future.

Clinical management of heterozygous familial hypercholesterolaemia

Rationale for lowering LDL cholesterol treatment goals in children with heterozygous familial hypercholesterolaemia

Key recommendations from the 2015 EAS consensus statement on the management of HeFH in children were to start pharmacological treatment at 8 years of age and to reduce LDL-C by 50% from baseline at 8–10 years and to 3.5 mmol/L (135 mg/dL) at >10 years.⁴ However, it is increasingly recognized that treatment of FH should focus on reducing the cumulative burden of LDL-C, a strong predictor of ASCVD,^{82,83} supporting earlier and more intense treatment to prevent the development of atherosclerosis in childhood. Carotid intima-media thickness




Figure 2 Cumulative LDL cholesterol exposure in individuals with or without familial hypercholesterolaemia and the impact of starting lipid-lowering therapy at 6 years or 18 years in heterozygous familial hypercholesterolaemia. Values in boxes are the mean LDL cholesterol concentration (in mmol/L) in the time period between the dots. To convert LDL cholesterol from mmol/L to mg/dL, multiply the mmol/L value by 38.67. The threshold for doubling the risk of atherosclerotic cardiovascular disease is 175 mmol/L $\times$ years (6800 mg/dL $\times$ years). Data are from Starr *et al.*,¹⁷ Vuorio *et al.*,⁹³ Reijman *et al.*,^{35,94} Tromp *et al.*,⁹⁵ Zhang *et al.*,⁸³ and Ibrahim *et al.*⁸² ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolaemia; HeFH, heterozygous familial hypercholesterolaemia; HoFH, homozygous familial hypercholesterolaemia; LDL-C, LDL cholesterol; LLT, lipid-lowering therapy

(cIMT), an indicator of early arterial injury,⁸⁴ has been shown to be greater in children with FH than their unaffected siblings,¹¹ with evidence of significant differences before the age of 10 years.¹² Numerous studies have shown that LLTs are safe and effective at reducing LDL-C concentrations in children with FH and that appropriate treatment at a young age can markedly reduce cIMT.^{85–88} Thus, regression of atherosclerotic lesions is possible if treatment starts early.

New classes of LLTs are now available and several LLTs have been approved from the age of 6 years, allowing lower LDL-C treatment goals to be achieved and treatment to start earlier if considered appropriate. In this current EAS consensus statement, we propose starting pharmacological treatment of HeFH in the first decade of life, ideally from 6 years (but with the precise age decided by the treating physician in discussion with the family). We also propose an LDL-C treatment goal of ≤ 3.5 mmol/L (135 mg/dL) in children aged 6 to <10 years and a lower treatment goal of ≤ 3.0 mmol/L (115 mg/dL) in children from 10 years or from 6 years if other major risk enhancers are present (see Table 1 and below). This lower treatment goal was selected based on a recent study showing that an increase in plaque volume over a 6-month period in children with HoFH can be prevented if the time-weighted cumulative LDL-C exposure is reduced to ≤ 3.0 mmol/L (115 mg/dL) per year.⁸⁹ However, shared decision-making is required to ensure that the optimal treatment strategy is chosen for the individual child,^{90,91} with an emphasis on starting treatment of any intensity before

puberty and ensuring adherence to treatment. A comparison of these modified LDL-C treatment goals with those presented in the 2015 EAS consensus statement is presented in Table 1.

Why is it important to focus on cumulative LDL cholesterol exposure?

Although cumulative LDL-C exposure drives cardiovascular risk in individuals with FH, current treatment guidelines are based on LDL-C concentrations at the time of diagnosis.^{82,92} The limitation of these guidelines is exemplified in Figure 2. The risk of symptomatic ASCVD doubles when the cumulative LDL-C burden crosses a threshold of 175 mmol/L (6800 mg/dL) $\times$ years.⁸³ In individuals without FH, this threshold is crossed on average after the age of 60 years. This threshold, however, is reached before the age of 33 years in an individual with untreated HeFH and by 12 years in a child with untreated HoFH [assuming mean LDL-C concentrations of 5.4 mmol/L (210 mg/dL) and 15.6 mmol/L (600 mg/dL), respectively].^{35,94,95} Treatment with statins (or other LLTs) will change this trajectory, and the earlier treatment is started the better. Thus, for an individual with HeFH, starting moderate- to high-intensity statin at 18 years will increase the age at which the threshold is reached to almost 50 years, but starting low- to moderate-intensity statin at 6 years will increase the age at which the threshold is reached to almost 60 years (i.e. another decade of symptom-free survival and close to those without FH).

It is important to note that the focus should not only be on starting treatment early but also on intensifying sufficiently and adhering to treatment to reduce the cumulative LDL-C exposure. A recent study in individuals with HeFH highlighted this point by showing that the prevalence or volume of coronary plaque did not differ between groups divided by age of treatment start (mean age at start of LLT: early, 15 ± 4 years; late, 37 ± 4 years).⁸² However, the risk of ASCVD was markedly lower in those with below-median cumulative LDL-C exposure [$175 \text{ mmol/L (6800 mg/dL)} \times \text{years}$] than in those with above-median cumulative LDL-C exposure.⁸²

Other major risk enhancers that may trigger lower LDL cholesterol treatment goals

The 2015 EAS consensus statement on the management of HeFH in children emphasized treatment and control of additional risk factors but did not propose altering LDL-C targets.^{4,92} However, epidemiologic studies indicate that the presence of conventional risk factors increases risk equivalent to an increase of LDL-C of $\sim 0.75 \text{ mmol/L (30 mg/dL)}$.⁹⁶ Here, we propose lowering the LDL-C treatment goal by 0.5 mmol/L in children with FH between 6 and <10 years if they have other major risk enhancers (see [Table 1](#) and discussed below). Only risk factors that would dramatically increase risk and cannot be corrected by lifestyle have been selected as major risk enhancers.

Lipoprotein(a) concentrations are primarily genetically determined, and thus elevated concentrations are potentially harmful from childhood onwards.⁹⁷ Although pharmacological agents designed to lower Lp(a) are being evaluated in clinical trials in adults,⁹⁸ paediatric studies are not anticipated in the near future. Atherosclerotic cardiovascular disease risk rises continuously with increasing Lp(a)⁹⁹ and a clinically relevant Lp(a) concentration is hard to define. We propose using a high cut-off, $\geq 250 \text{ nmol/L (120 mg/dL)}$,^{15,16} as a trigger to lower the LDL-C treatment goal in children with HeFH from 6 to <10 years of age to the treatment goal of those ≥ 10 years of age, as there are currently no other ways to correct for this increased risk related to elevated Lp(a).

If a child with HeFH has diabetes or hypertension, known cardiovascular risk factors in FH,¹⁰⁰ we propose lowering the LDL-C treatment goal from 6 years. This is also the case in the rare instances of children with HeFH and diseases such as chronic inflammatory diseases (e.g. rheumatoid arthritis, lupus, and inflammatory bowel disease), chronic kidney disease, Kawasaki disease, HIV, and cancer survivorship, all of which are associated with an increased risk of ASCVD.¹⁰¹

Smoking and obesity are also known to increase the risk of ASCVD in FH.¹⁰⁰ A more recently recognized lifestyle risk factor is the use of e-cigarettes (vaping),^{102,103} which is increasing in (young) children. Children with HeFH should be discouraged from starting to smoke or vape by discussing the risk at first visit. If a child with HeFH already smokes or vapes or has developed obesity, extra lifestyle advice is required rather than striving for lower treatment goals.

Can cardiovascular imaging support risk stratification in children with heterozygous familial hypercholesterolaemia?

Imaging to detect subclinical atherosclerosis is known to add information about future cardiovascular risk in adults with

FH,^{104,105} but it is not routinely used in the clinic in children with HeFH. Carotid intima-media thickness is used in research settings to monitor response in a treatment group.^{87,106} However, we do not propose using cIMT to monitor atherosclerosis in clinical practice in individual children with HeFH because of the following limitations: (i) many centres have little experience of cIMT, (ii) normal values of cIMT are not known in children, and (iii) across and within centres, there are variations in measurement protocols, the location of the measurement (common carotid artery, internal carotid artery, bulb, or a combination of these), the type of equipment used, the individuals performing the ultrasound, and variability in interpretation by different readers.

Subclinical atherosclerosis in adults can be assessed using coronary artery calcium (CAC) scoring, determined by computed tomography (CT), and coronary CT angiography (CCTA), which can assess both calcified and non-calcified plaques. However, calcium may not be present despite significant atherosclerosis,⁴ and a recent study showed that CCTA-detected atherosclerosis was not present in children with severe HeFH.¹⁰⁷ Therefore, given the increased lifetime risk of exposure to radiation, we do not advise using CAC scoring or CCTA in children with HeFH.

Lifestyle measures

Lifestyle measures should be the first step in the management of a child diagnosed with HeFH,¹⁰⁸ although a healthy lifestyle alone is generally not sufficient to achieve LDL-C treatment goals. In cases of early diagnosis, some children are too young to start pharmacological treatment but not too young to be introduced to a healthy lifestyle. Lifestyle measures, implemented in parallel with or followed by timely pharmacological treatment, give the child and their parents a feeling of being in control. In the current era with genetic confirmation of a diagnosis, we can identify children carrying a mild FH-causing variant, with LDL-C levels close to treatment goal, who might benefit from lifestyle measures alone.

Regular physical activity should be highly encouraged. Smoking and vaping should be strongly discouraged. Obesity should be avoided and other cardiovascular risk factors (e.g. chronic inflammatory diseases and chronic kidney disease) should be treated. Nutritional management goals for children with HeFH are to reduce LDL-C concentrations and global cardiovascular risk while maintaining optimal growth and neurocognitive development.¹⁰¹ We propose implementing nutritional advice for the entire family and promoting a healthy diet rather than focusing solely on food categories.^{109,110}

Dietary components that should be limited or promoted in children with FH are listed in [Table 2](#). A cautious low-fat diet has shown to be safe in children aged 8–10 years with elevated LDL-C.¹²¹ In the randomized Special Turku Coronary Risk Factor Intervention Project, a low-fat diet was shown to be safe in children from 7 months of age.¹²⁶ Although plant stanols and sterols lower LDL-C,^{127–129} no intervention studies showing an effect of these dietary supplements on ASCVD have been performed and therefore no clear recommendation can be made.^{15,130}

Outpatient dietary counselling in children with FH has been shown to increase the consumption of products with a more favourable fatty acid and cholesterol composition¹³¹ and improve

Table 2 Dietary components that should be limited or promoted in children with familial hypercholesterolaemia	
Limit	Goals
Dietary cholesterol ^{111–114}	200–300 mg/day
Saturated and trans fatty acids ^{113,115,116} : processed foods, animal fat, red meat, whole-fat dairy products, pastries, palm oil, and coconut oil	<7% DEI
Added simple sugars, including fructose ¹¹⁷	<10% DEI
Promote	Goals
Balanced diet	Carbohydrate 45%–60%, fat 25%–35%, protein 12%–15% of DEI adapted to age ¹¹⁸
Structured complete and regular meals; stress importance of breakfast ^{119,120}	
Low-fat dairy foods ¹²¹	
Long-chain PUFA ¹²² : oily fish twice a week, pulses, nuts, seeds, tofu, vegetable oils (rapeseed, soybean, corn, sunflower)	Promote n-3 PUFA; total PUFA 5%–10% DEI
Monounsaturated fatty acids ^{123,124} : vegetable oils (rapeseed, olive, canola, peanut, sesame), avocados, nuts, and seeds	10%–15% DEI
Fibre ¹²⁵ : fresh fruits and vegetables, wholemeal bread, cereals, legumes	25–40 g/day, 7%–13% soluble fibres
Intake of lean and fatty fish, shellfish, lean chicken and turkey (white meat, skinless), limited lean red meat (>93% lean, fat trimmed, free range) ¹²³	

DEI, daily energy intake; PUFAs, polyunsaturated fatty acids.

the lipid profile of children.¹³² Saturated fat should be substituted with polyunsaturated fat.¹³³ Risks of nutritional interventions in children with FH to be aware of and avoid include (i) insufficient intake of energy, essential fatty acids, and vitamin E¹³⁴ and (ii) the development of eating disorders.

Pharmacological treatment

Statin treatment initiated in childhood has been shown to reduce the risk of ASCVD in individuals with FH to that of the general healthy population.⁸⁷ As noted earlier, treatment should not only focus on ‘the lower the better’ but also ‘the earlier and the longer the better’. With the availability of new therapies, our proposed LDL-C targets can today nearly always be achieved in children with HeFH using a maximum of two drugs. To promote adherence to LLT, three drugs should be avoided as much as possible and only given in the rare cases when the treatment goal is not achieved otherwise.

Table 3 lists the LLTs currently approved in children, the age from which they are approved and the extent of LDL-C reduction to be expected with each therapy. A treatment algorithm for children with HeFH is presented in Figure 3.

Statins remain the first line of LLT in children with FH. Statin treatment is well tolerated among children, with few reports of side effects.^{4,156–164} High-potency statins such as rosuvastatin and atorvastatin should be preferentially considered for therapy initiation. The cumulative incidence of cardiovascular events and death from cardiovascular causes before the age of 40 has been shown to be lower amongst children with HeFH treated early with statins than amongst their parents with FH for whom statins were available much later in life.⁸⁷ The dose and/or intensity of statin given should be increased according

to the LDL-C concentration, residual LDL receptor (LDLR) activity and age-dependent treatment goal. Lipid profile, creatine kinase, and aminotransferases (alanine transaminase and aspartate transaminase) should be measured 8–12 weeks after increasing the dose or introducing a (new) statin and annually thereafter.

If LDL-C targets are not achieved with statin monotherapy but are close to goal [i.e. <4.0 mmol/L (155 mg/dL)], ezetimibe can be added.¹⁴⁶ In the rare case of statin intolerance,¹⁶⁶ consider reducing the statin dosage or switching to another statin.^{87,167,168} If the child remains intolerant to statins, consider replacing statins with ezetimibe. Ezetimibe monotherapy has been shown to reduce LDL-C concentrations in children between 6 and 10 years (by 27% after 12 weeks of treatment) and is very well tolerated.¹⁴⁵

If LDL-C concentrations on statin monotherapy are not close to goal [i.e. ≥4.0 mmol/L (155 mg/dL) measured at least twice], consider a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor instead of ezetimibe. The monoclonal antibody PCSK9 inhibitors evolocumab^{148,149} and alirocumab¹⁴⁷ are approved for children with HeFH from 10 years and 8 years, respectively, by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA); evolocumab is also approved for children with HoFH from 10 years.¹⁵⁰ The FDA recently approved inclisiran, a small interfering RNA PCSK9 inhibitor, for adolescents from 12 years with either (i) HeFH¹⁵¹ or (ii) HoFH and some residual LDLR function (i.e. excluding those with two LDLR null variants).¹⁵² It is currently being tested in children with HeFH from 6 years of age (NCT06597019) and in those with HoFH from 2 years of age (NCT06597006). Lerodalcicbep, a small binding protein inhibitor of PCSK9, has been tested in children from 10 years and adults

Table 3 Approved lipid-lowering therapies for children with familial hypercholesterolaemia¹³⁵

Lipid-lowering therapy	Age approved/tested	Approved (or tested) dose range and route of administration	LDL-C reduction ^a	Key publications
Statins (β -hydroxy β -methylglutaryl-CoA reductase inhibitors)				
Pitavastatin	≥ 6 years	1–4 mg (PO)	23%–39% (placebo adjusted)	Braamskamp et al., 2015 ¹³⁶
Rosuvastatin	≥ 6 years	5–20 mg (PO)	35%–45%	Braamskamp et al., 2015 ¹³⁷ Stein et al., 2017 ¹³⁸ (HoFH)
Pravastatin	≥ 8 years	20–40 mg (PO)	24% (placebo adjusted)	Wiegman et al., 2004 ⁸⁵
Atorvastatin	≥ 10 years	10–20 mg (PO)	40% (placebo adjusted)	McCrintle et al., 2003 ¹³⁹ Raal et al., 2000 ¹⁴⁰ (HoFH)
Fluvastatin	≥ 10 years	20–80 mg (PO)	34%	van der Graaf et al., 2006 ¹⁴¹
Lovastatin	≥ 10 years	10–40 mg (PO)	17%–27% (placebo adjusted)	Stein et al., 1999 (in boys) ¹⁴² Clauss et al., 2005 (in girls) ¹⁴³
Simvastatin	≥ 10 years	10–40 mg (PO)	31%–40% (placebo adjusted)	de Jongh et al., 2002 ¹⁴⁴
Inhibitor of intestinal cholesterol absorption				
Ezetimibe	≥ 6 years EMA; ≥ 10 years FDA	10 mg (PO)	27% as monotherapy (placebo adjusted) 15% on top of simvastatin (placebo adjusted)	Kusters et al., 2015 ¹⁴⁵ van der Graaf et al., 2008 ¹⁴⁶
PCSK9 inhibitors				
Alirocumab	≥ 8 years (not approved for HoFH <18 years)	If <50 kg: 150 mg (SC) q4w and 40 mg (SC) q2W If ≥ 50 kg: 300 mg (SC) q4w and 75 mg (SC) q2W	34%–43% on top of background LLT (placebo adjusted)	Santos et al., 2024 ¹⁴⁷
Evolocumab	≥ 10 years	420 mg (SC) q4w and 140 mg (SC) q2w	38% on top of background LLT (placebo adjusted)	Santos et al., 2020 ¹⁴⁸ Santos et al., 2022 ¹⁴⁹ Raal et al., 2024 ¹⁵⁰ (HoFH)
Inclisiran	≥ 12 years ^b	300 mg (SC) at 0 and 90 days and then q6m	29%–34% on top of background LLT (placebo adjusted)	Wiegman et al., 2026 ¹⁵¹ Wiegman et al., 2025 ¹⁵² (HoFH)
Bile acid sequestrant				
Colesevelam	10 years (avoid in HeFH ^c)	1.875–3.75 g (PO)	6%–12% (placebo adjusted)	Stein et al., 2010 ¹⁵³
Angiotensin-like 3 inhibitor				
Evinacumab	≥ 6 months EMA; ≥ 1 year FDA (approved for HoFH)	15 mg/kg (IV) q4w	48%	Wiegman et al., 2024 ¹⁵⁴ (HoFH)
Microsomal triglyceride transfer protein inhibitor				
Lomitapide	≥ 2 years ^b (approved for HoFH)	2–60 mg based on age, weight, and tolerability (PO)	53%	Masana et al., 2024 ¹⁵⁵ (HoFH)

EMA, European Medicines Agency; FDA, Food and Drug Administration; HeFH, heterozygous familial hypercholesterolaemia; HoFH, homozygous familial hypercholesterolaemia; IV, intravenous; LDL-C, LDL cholesterol; LLT, lipid-lowering therapy; PO, oral; SC, subcutaneous.

^aLDL-C reductions are mean, median, or ranges, and placebo adjusted where indicated.

^bApproved by the US FDA but not yet by the EMA.

^cFor HeFH, use only in situations when the newer LLTs are not available or tolerated.

To date, no data are available on the use of the adenosine triphosphate-citrate lyase inhibitor bempedoic acid in children or adolescents; however, a Phase 2 trial has recently been completed in children with HeFH aged 6–17 years (NCT05694260).




Figure 3 Treatment algorithm for children with heterozygous familial hypercholesterolaemia. *Ezetimibe reduces low LDL cholesterol concentrations in statin-treated children by ~15% (Table 3), which may be sufficient when LDL cholesterol <4.0 mmol/L. If greater reductions are needed to achieve the treatment goal, add PCSK9 inhibitors to statin treatment (or to ezetimibe if a child is statin intolerant). Only in rare cases should three drugs be used. **PCSK9 inhibitors are approved for children with familial hypercholesterolaemia from 8 years (alirocumab), 10 years (evolocumab), or 12 years (inclisiran; Food and Drug Administration approved). To convert LDL cholesterol from mmol/L to mg/dL, multiply the mmol/L value by 38.67

with HoFH¹⁶⁹ and is currently being evaluated in a phase 3 trial in children with HeFH from 6 years (NCT07102511). The oral PCSK9 inhibitor enicotide is currently being tested in a Phase 2 trial in children with HeFH from 6 years of age (NCT07058077).

Of the bile acid sequestrants, colestevam is the best tolerated.¹⁵³ However, given the availability of new LLTs, these agents should be considered only for specific situations where newer medications are unavailable or not tolerated. A Phase 2 trial for bempedoic acid, an oral inhibitor of cholesterol

biosynthesis, has recently been completed in children with HeFH aged 6–17 years (NCT05694260).

In situations where LDL-C goals are not met despite the use of age-appropriate, guideline-recommended statin doses and when PCSK9 inhibitors are unavailable, consider using the highest tolerated doses of statins and ezetimibe, along with a cholesterol-lowering diet. Bile acid sequestrants could also be an option (as noted above), and supplementing with plant sterols/stanols may help reduce LDL-C in these situations, if available and affordable.

Does sex matter?

Although men with FH have a higher risk of developing premature ASCVD, women with FH have a higher LDL-C burden compared with men at a young age¹⁷⁰ owing to (i) higher LDL-C in childhood^{6,170,171} and (ii) treatment discontinuation in relation to family planning, pregnancy and breastfeeding (on average, women with FH have 2.3 years pregnancy-related off-treatment time).¹⁷² To compensate for the increased LDL-C burden in relation to family planning, pregnancy and breastfeeding, it is particularly important to start treatment as early in girls as in boys.

Safety

As observed in all paediatric FH clinical trials, the frequency of side effects in children is much lower than in adults. The most common reported side effects of statins are muscle symptoms. A meta-analysis of large-scale, randomized, double-blind trials in adults concluded that most of the muscle symptoms reported are probably not caused by statin therapy.¹⁷³ Elevations in creatine kinase are rarely observed in children.^{157,158} Increases in concentrations of hepatic aminotransferases are rarely observed with statins in children^{157,158} and are not associated with an increased risk of liver disease in adults.¹⁷⁴

Statin use in adults is associated with a small increased risk of new-onset diabetes especially in people who are at risk of developing diabetes.¹⁷⁵ Changes in insulin sensitivity were not observed in children and adolescents after 7 months of statins (in contrast to adults where changes could be observed after 10 weeks on treatment).¹⁷⁶ Although it is not possible to exclude a potential long-term risk of Type 2 diabetes in children with FH who start statin therapy at a young age,¹⁶⁵ any risk will likely be outweighed by the highly proven cardiovascular benefit of statin therapy.¹⁵⁹ Nevertheless, this potential risk reinforces the importance of emphasizing a healthy lifestyle to avoid obesity in children with FH.

Ezetimibe is well tolerated in children and adolescents; reported adverse events do not differ from those reported using placebo or statins alone.^{145,146,177} Bile acid sequestrants can cause gastrointestinal side effects.¹⁵³

The safety of evolocumab and alirocumab has been tested in children and adolescents with HeFH in double-blind trials with open-label extension phases lasting 24 and 80 weeks, respectively.^{147–149,178} Both medications were well tolerated, with the most frequent adverse events being injection site reactions compared with placebo. There were no issues related to liver and muscle function, growth, pubertal maturation, or neurocognitive parameters.¹⁷⁸ Additionally, no adverse events were reported concerning glucose homeostasis, liposoluble vitamins, or steroid hormones. No anti-drug antibodies were detected. Inclisiran is reported to be well tolerated, with injection site reactions being the most frequent adverse events.¹⁵¹ However, data on the long-term (5–10 years) use of PCSK9 inhibitors in children are not yet available.

Clinical management of homozygous familial hypercholesterolaemia

Importance of early diagnosis

Homozygous familial hypercholesterolaemia is suspected in individuals with untreated LDL-C concentrations >10 mmol/L

(>400 mg/dL) or evidence from medical and family history and/or genetic testing.⁵ Classical symptoms are cutaneous or tendon xanthomas before the age of 10 years.⁵ Premature onset of atherosclerosis mainly affects the aortic root, coronary ostia and the aortic valves and can be observed in the first two decades of life.¹⁷⁹ Aortic disease may progress even when LDL-C concentrations are reduced, potentially as a result of haemodynamic stress and progressive fibrosis.^{4,180} Therefore, it is important that HoFH is diagnosed as early as possible and that treatment starts soon after diagnosis.

Children with clinically suspected HoFH (mainly because of xanthomas) or at risk of HoFH (as both parents are known to have FH) should be tested as early as possible (from newborn up to 2 years of age), with measurement of LDL-C concentrations followed by genetic confirmation.⁹² As pointed out in the 2023 EAS consensus statement on HoFH,⁵ implementation of current guidelines should be improved to promote early detection of HoFH. This earlier statement proposed that paediatric guidelines should be expanded to include newborn lipid screening in high-risk settings and national screening programmes should be established where these are lacking. Early life lipid screening is supported by the recently announced European Union Safe Hearts Plan.⁴⁷

It is important to note that clinically defined HoFH does not necessarily imply homozygosity for the same allele in a strict genetic sense, but instead it encompasses all biallelic pathogenic variants that impair the LDLR pathway. An individual with genetically confirmed HoFH will have inherited two pathogenic variants in one (biallelic monogenic HoFH) or two (biallelic digenic HoFH) of the FH-causing genes *LDLR*, *APOB*, and *PCSK9* or the FH-associated gene *LDLRAP1* (see Table 1 in Cuchel et al.⁵). If the child has consanguineous parents or is from a country with a high rate of genetic founder effects, the two variants may be identical (previously called 'true' HoFH; now called 'biallelic identical variant' HoFH). In other cases, a child will have two different pathogenic variants either in the same causative gene (previously called 'compound heterozygous FH'; now called 'biallelic different variant' HoFH) or in two different causative genes (previously called 'double heterozygous FH'; now called 'digenic' HoFH). Most commonly, a child with HoFH will have inherited one FH-causing variant from each parent, both of whom have HeFH. However, in the rare case of digenic HoFH, it is possible that one parent has digenic HoFH and the other parent has no pathogenic FH variant and the child inherited both variants from the digenic parent. All of these different genetic scenarios mean that the individual has HoFH, and we propose that genetic laboratory reports should include text stating this clearly to avoid confusion of interpretation and eligibility for future treatment options.

Use of cardiovascular imaging

Children diagnosed with HoFH should be screened for subclinical ASCVD including aortic valve disease by cardiovascular imaging, as described in the 2023 EAS consensus statement on HoFH.⁵ Coronary computed tomography angiography should be performed at least once after age 3 years and thereafter as clinically indicated to guide treatment decision-making and tailor treatment frequency and intensity.¹⁸¹ The rapid development of CCTA, particularly photon-counting CT with its increasingly




Figure 4 Treatment algorithm for children with homozygous familial hypercholesterolaemia. * $<2\%$ LDL receptor activity. **Evinacumab is approved by the European Medicines Agency and the US Food and Drug Administration from the age of 6 months and 1 year, respectively. Lomitapide is approved by the Food and Drug Administration from 2 years

detailed plaque-characterization capabilities, underscores the value of this modality in children with HoFH.^{182,183}

LDL cholesterol treatment goals

The LDL-C treatment goal in children/adolescents with HoFH is ≤ 3.0 mmol/L (115 mg/dL) from diagnosis, in agreement with the 2023 EAS consensus statement on HoFH.⁵ A reduction to this concentration is supported by the recent study showing that an increase in plaque volume over a 6-month period was

prevented in children with HoFH who achieved a time-weighted cumulative LDL-C exposure of ≤ 3.0 mmol/L (115 mg/dL) per year.⁸⁹ For children with ASCVD, a treatment goal of ≤ 1.8 mmol/L (70 mg/dL) should be considered.¹⁸¹

Lifestyle measures and pharmacological treatment

A treatment algorithm for children with HoFH is presented in Figure 4. A step-by-step treatment plan is proposed starting

with a healthy diet and a combination of high-intensity statin and ezetimibe at the time of diagnosis.⁵ Regular physical activity should be highly encouraged. Smoking and vaping should be strongly discouraged. As statins and PCSK9 inhibitors are dependent on LDLR function, their effectiveness depends on the level of residual LDLR activity. If LDL-C concentrations are not at goal on statins and ezetimibe within a few weeks and the child does not have two *LDLR* null variants, a PCSK9 inhibitor should be added. PCSK9 inhibitors should be continued if the LDL-C reduction is >15% after one to two dose applications. LDL receptor-independent treatments should be considered instead of adding a PCSK9 inhibitor when a child is known to have no LDLR activity or when treatment goals are not achieved with these initial treatments (see below).

LDL receptor-independent pharmacological treatments are evinacumab (administered by intravenous infusion every 4 weeks) and lomitapide (administered orally). Evinacumab is a human monoclonal antibody that targets angiopoietin-like 3, an inhibitor of lipoprotein lipase and endothelial lipase, and thereby reduces LDL-C concentrations.¹⁸⁴ Evinacumab has been shown to reduce baseline LDL-C by 48% in children with HoFH aged 5–11 years after 24 weeks of treatment (Table 3).¹⁸⁵ A study in two adolescents (aged 12 and 16 years) with *LDLR* null/null variants showed that plaque volume was reduced by 76% and 85% after 6 months on evinacumab.¹⁸⁶ Evinacumab has recently been approved by the EMA and FDA for the treatment of children with HoFH from the age of 6 months and 1 year, respectively. It can therefore be used to treat children with no LDLR activity at an earlier age than lipoprotein apheresis (see below).

Lomitapide is a microsomal triglyceride transfer protein inhibitor¹⁸⁷ and has been shown to reduce LDL-C by around 50%¹⁸⁸ (Table 3). Because of its mechanism of action, hepatic and gastrointestinal adverse effects are of concern. A low-fat diet may help to avoid these side effects. A recent open-label, single-label Phase 3 trial in children aged 5–17 years showed that lomitapide was effective at reducing LDL-C in this age group and adverse events were mostly mild.¹⁵⁵ Lomitapide has recently been approved by the FDA from the age of 2 years.

Lipoprotein apheresis

Lipoprotein apheresis is an effective LDLR-independent option to rapidly lower LDL-C in children with HoFH. Expert consensus states that lipoprotein apheresis be considered as early as age 2–3 years when the target LDL-C concentration is not achieved with healthy lifestyle and pharmacological therapy (Figure 4).^{5,181,189–191} Although there are no randomized, placebo-controlled trials, there is increasing evidence that lipoprotein apheresis started in childhood leads to longer cardiovascular event-free survival.^{94,190,192}

Several lipoprotein apheresis methods exist to selectively remove LDL and other apolipoprotein B-containing lipoproteins, including Lp(a).^{181,191} This treatment also removes inflammatory and thrombogenic substances.¹⁹¹ At each visit, blood is withdrawn from the body, anticoagulated, the lipoproteins removed and the remainder returned over a 2–3 h period. The preferred access is through peripheral veins or arterio-venous fistula.^{181,193} The frequency of visits ranges from twice a week to once every 4 weeks, with once every 1–2 weeks being the most common.¹⁹⁰

Biweekly lipoprotein apheresis in children and adolescents has been shown to reduce baseline LDL-C concentrations by

75% acutely and by 48% chronically.¹⁹³ Because LDL-C concentrations rebound quickly after lipoprotein apheresis, we consider that the Kroon formula should be used to estimate the mean reduction between lipoprotein apheresis sessions¹⁹⁴:

$$\text{LDL-C}_{\text{mean}} = \text{LDL-C}_{\text{post}} + K(\text{LDL-C}_{\text{pre}} - \text{LDL-C}_{\text{post}})$$

where $\text{LDL-C}_{\text{pre}}$ is the LDL-C concentration directly before the session, $\text{LDL-C}_{\text{post}}$ is the LDL-C concentration directly after the session, and K is the rebound coefficient. K is estimated to be 0.65 for adults with HoFH on statin therapy and undergoing bi-weekly apheresis.¹⁹⁵ However, the formula has not been validated in children or when the procedure is performed with an interval different than biweekly. A high $\text{LDL-C}_{\text{pre}}$ in children could indicate the need for more frequent apheresis or for the addition of other LDLR-independent therapies even if the Kroon formula estimates a mean $\text{LDL-C} \leq 3.0$ mmol/L (115 mg/dL).

Safety, quality of life, and emotional impact of the therapy should be considered. Serious adverse effects such as hypotension and anaphylactoid reactions are rare. Every effort should be made to employ skilled nurses with expertise in catheter placement in children, and interpersonal skills are essential to establish close relationships with both the child and caretaker(s). Prolonged travel time, school and work demands, and high cost may limit adherence to and availability of this procedure.

The combination of lipoprotein apheresis with LDLR-independent drugs such as evinacumab makes it now possible for the most severely affected children with *LDLR* null/null variants to reach LDL-C goals and even rapidly regress plaque.¹⁸⁶ The newest treatments, however, might not always be available. If lipoprotein apheresis is not available or feasible (e.g. in low- or middle-income countries or in children with small blood volume), plasma exchange should be considered.⁹²

Liver transplantation

In exceptional cases, liver transplantation can be considered in children with HoFH who have persistently elevated LDL-C concentrations and ASCVD despite optimal available and tolerated treatment.¹⁹⁶

Clinical management of sitosterolaemia and lysosomal acid lipase deficiency

For sitosterolaemia, individuals should avoid plant sterols. The primary pharmacological treatment is ezetimibe, which acts by reducing intestinal absorption of plant sterols.¹⁹⁷

For LALD, individuals should consume a low-fat diet. The primary pharmacological treatment is sebelipase alfa (lipid-metabolizing enzyme replacement), which has been shown to reduce disease-related hepatic and lipid abnormalities.¹⁹⁸

Transition to an adult model of health care for familial hypercholesterolaemia

The transition from paediatric to adult health care involves changes in care teams and system design. As a result,

Box 3 Proposals to facilitate a smooth transition to an adult model of health care for familial hypercholesterolaemia

- (1) Children with FH should be taught about their condition and its management as early as possible, and definitely by the age of 10 years.
- (2) The importance of diet, healthy lifestyle measures, and avoidance of smoking/vaping should be explained and stressed before puberty.
- (3) Adherence to LLT should be monitored, especially during puberty.
- (4) Girls should be given advice on contraception.
- (5) If adolescents wish, they can be seen (partly) without their parents.
- (6) Before transfer to the adult service, adolescents should be made aware that from age 18: (i) LLTs other than those used in childhood are approved and prescribed and (ii) LDL-C treatment goals will be lowered to 1.8 mmol/L (70 mg/dL).
- (7) Upon transfer to the adult service, the hospital physician taking over care from the paediatrician should actively review and, if necessary, adjust the lipid-lowering regimen. This should be clearly emphasized during the hand-over of care.
- (8) If other major risk enhancers are present, one could strive from age 16 for a lower LDL-C goal to facilitate transition to adulthood when the treatment goal will be lowered to LDL-C <1.4 mmol/L (55 mg/dL) according to the 2025 focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.¹⁵
- (9) An adolescent with FH, and especially those with HoFH, should preferably attend a transition clinic or a joint clinic with the paediatrician and internist/cardiologist at least once before transfer to the adult service.

adolescents and young adults are often overlooked, leading to a lack of follow-up and loss of compliance. Moreover, adolescents and young adults often consider health care of low importance compared with the other aspects of their transition to adulthood, such as education, employment and relationships. It is, therefore, important to start the process of empowering children with FH with knowledge about their condition and its management as early as possible and by 10 years at the latest. Better education of young FH patients should improve long-term adherence to clinical management.

Although not frequent in children and adolescents with FH, cardiac events can occur, especially in those with HoFH and in young adults with severe HeFH. Therefore, it is extremely important to ensure that the symptoms of acute cardiac events and the necessity of seeking prompt medical assistance are recognized by young people with FH who often transfer to adult care at the same time as starting to live independently.

Key proposals for transition from childhood to adulthood are summarized in [Box 3](#).^{199,200}

Box 4 Proposals for future studies in paediatric familial hypercholesterolaemia

Establish thresholds in imaging for excessive subclinical atherosclerosis.
 Cost-effectiveness studies to compare screening strategies. Develop more reliable tools to be used for newborn screening.
 Include FH in genomic newborn screening studies.
 Demonstrate the benefit of polygenic risk scores in children.
 Investigate the effectiveness of a cholesterol-lowering diet on ASCVD incidence and mortality.
 Examine the combined risk of FH and elevated Lp(a) in childhood.

Implementation science and practice

Given the overall lack of success in translating evidence into routine practice to date, models of care for children and adolescents with FH should embed processes for implementation, operationalization, and evaluation. Application of implementation science can effectively inform such models.^{92,201,202} Strategies that should be considered include personalized and transitional care plans, psychologically and culturally appropriately shared decision-making, tools to improve communication and adherence, use of multi-disciplinary teams, shared care with family medicine,⁹¹ general support for clinicians, application of digital technologies, sharing of resources and expertise among services, and dedicated funding mechanisms. Support from advocacy groups and analyses of quality clinical registry data should be used to influence health policy and improve services. Government funding for comprehensive care of all children and adolescents with HoFH must be secured to establish centres of excellence and schemes for accessing new therapies.^{5,92,203,204}

Future research and conclusions

Further research in paediatric FH is required as indicated in [Box 4](#). A particular focus should be on providing high-level evidence for the effective use of implementation science.^{69,201,202} The proposed LDL-C cut-offs for diagnostic criteria are based on observational data.¹⁷ The panel acknowledges that the proposed LDL-C treatment goals have not been tested in clinical trials. Similar to the LDL-C treatment goals recommended in adults,¹⁵ the goals for treatment of children with FH have been derived indirectly from clinical trials comparing LLT with placebo or different dosages of LLT.

Despite advances in understanding the pathogenesis of FH and how to manage the disorder, FH remains underdiagnosed and undertreated. Detection and initiation of treatment of HeFH before puberty is critical to ensure that an individual's lifetime cumulative LDL-C burden is reduced, which would lead to substantially reduced cardiovascular risk and improved life expectancy. Children who start treatment of FH before puberty will not only have additional years of benefit but also adhere better to lifestyle and pharmacological treatment compared with those who start later in adolescence.

To increase detection, we strongly encourage all countries to establish a paediatric screening programme, with the age range for screening tailored to best fit country-specific contexts, but ideally within the first decade of life. To improve diagnostic sensitivity, we propose lower LDL-C concentrations for suspecting FH in a child than those presented in the 2015 EAS consensus statement on FH in children.⁴ We suggest including Lp(a) in the lipid profile to test at least once from the age of 5 and, if elevated, testing Lp(a) in (grand)parents. In addition, we present concrete updated guidance for managing both HeFH and HoFH. For HeFH, we propose lower LDL-C treatment goals than those presented in the 2015 consensus; these revised goals can be achieved in most cases using no more than two drugs because of the availability of new classes of LLTs.

Future research is required as indicated above, with the goal of ensuring that all individuals with FH are identified in childhood, start on best standard of care before puberty, and adhere to such care throughout their lifespan.

Supplementary data

Supplementary data are available at [European Heart Journal](https://academic.oup.com/eurheartj/article/47/26/3324/8691080) online.

Declarations

Disclosure of Interest

C.J.B. is a consultant for Boehringer Ingelheim, Novartis, SOBI, and Takeda, a board member of Technoclone, and has received honoraria as a speaker and/or grants for travel and research from Amgen, Novartis, and SOBI. M. Bourbon is a consultant for Ultragenyx, Sobi, and Alexion. She has received support from Novartis (for publication) and Ultragenyx (annual meeting travel and accommodation expenses) and research grants from La Caixa Foundation and Horizon Europe. She is part of the scientific advisory committee of the FH Europe Foundation. T.F. is a paid consultant and advisory board member for Medison, Sobi, and Exceed Orphan. He has received speaker honoraria from Novartis and Ultragenyx. He participated in an FH screening project in Slovakia supported by Amgen and is participating in an FH screening project in pre-school children supported by Roche (he did not receive payment from either company). He has received research grants from the Ministry of Health in the Czech Republic and from the EU. He is a member of the scientific advisory committee of the FH Europe Foundation. S.S.G. is a consultant for Esperion Data and a member of the drug and safety monitoring board for Merck. He has received research grants from the National Institutes for Health (related to FH and to implementation science and genomics) and the CDC (related to hypertension). S.G.-P. has received speaker honoraria and travel grants from Ultragenyx, Sobi, Chiesi, Rhythm, and Vertex. She

has participated in clinical trials run by Amgen, Sanofi, and Regeneron/Ultragenyx and is participating in clinical trials run by Novartis, Esperion, and Arrowhead. She has received research funding from Ultragenyx, Novartis, Amgen, Chiesi, Sobi, Sanofi, and Rhythm. U.G. has received speaker honoraria from Novartis, PTC Therapeutics, and Ultragenyx and has participated as a PI in clinical trials sponsored by Novartis and PTC Therapeutics. He is a member of the FH Europe Scientific Committee, a World Heart Federation emerging leader and vice-president of the Slovenian Heart Foundation. K.B.H. has received speaker honoraria from Sanofi, Menarini, and Ultragenyx. Through the Research Council of Norway, she has been involved in industrial collaboration projects with e.g. Tine, Mills, and Mowi. Through the Norwegian Seafood Research fund, she has collaborated with EPAX. She has received a travel grant from Ultragenyx and is a member of the scientific advisory committee of the FH Europe Foundation and advisor to the Norwegian FH patient organization. S.E.H. is chief scientist of StoreGene (no remuneration) and a consultant for Verve Therapeutics. He has received funding from the UK National Institute for Health and Care Research Health Technology Assessment. B.A.H. is a consultant for Silence Therapeutics. She has received research grants from Silence Therapeutics paid to the institution (Amsterdam University Foundation) for salaries of PhD students. D.I. has received speaker honoraria from Chiesi, Sanofi, Daiichi Sankyo, and Sobi. She has participated in trials run by Novartis, Ionis, Amgen, and Lilly. C.P. has received a speaker honorarium from Ultragenyx. N.P. is a company consultant for Ultragenyx, Sanofi, Chiesi, Alexion and Amgen. He has received speaker honoraria from Chiesi and Ultragenyx. He has participated in trials run by Amgen and research financed by Amgen. He has received support from Alexion. F.J.R. has received research grants, honoraria, or consulting fees for professional input and/or delivered lectures from Amgen, MSD, Novartis, Sanofi, Regeneron, Ultragenyx, Chiesi, and LIB Therapeutics. He has participated in clinical trials with novel lipid-lowering drugs for the treatment of homozygous and heterozygous FH for MSD, Regeneron, Ultragenyx, Arrowhead, and LIB Therapeutics. Fees received from clinical trials are used to support the running of his research unit. He has received travel grants to attend and speak at international lipid meetings from the EAS, Ultragenyx, Chiesi, and LIB Therapeutics. He was the Secretary of the Lipid and Atherosclerosis Society of Southern Africa and was a board member of the International Atherosclerosis Society until 2024. U.R. has received honoraria for advisory board meetings from Esperion. J.R.v.L. received a research grant from Novartis. She has participated in clinical trials for Amgen, MSD, Novartis, Eli Lilly, New Amsterdam, and Ionis. She is on the steering board for MILOS (Daiichi Sankyo). S.R. declares equity from Heptabio; received honoraria as a consultant and/or speaker from Ultragenyx, Amgen, Sanofi, Ribocure, Wave Life Sciences, AstraZeneca, Chiesi, and Novartis; received

* Corresponding authors: Tel: +31630132065, Email: a.wiegman@amsterdamumc.nl (A.W.); Tel: +31652313132, Email: j.roetersvanlennep@erasmusmc.nl (J.R.v.L.)

† For list of other contributors, see [Appendix](#).

© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

research grants from AstraZeneca; and has acted as a principal investigator for Balance, Core, Horizon and Orion studies. V.S. has received speaker honoraria from Novartis, Sanofi, Amgen, and Daiichi Sankyo. R.D.S. is a consultant for Daiichi Sankyo, Eli Lilly, Esperion, Novartis, Novo Nordisk, and Ultragenyx. He has received speaker honoraria from Amgen, Novo Nordisk, Novartis, Eli Lilly, Daiichi Sankyo, Torrent, Libbs, and Chiesi. He has participated in trials run by Amgen, Novartis, Ionis, Sanofi/Regeneron, MSD, and Arrowhead and in research funded by Amgen, Novartis, Ionis, Sanofi/Regeneron, Esperion, MSD, and Arrowhead. He has received other support from Sanofi and research grants from Novartis. He is the World Heart Federation Editor in Chief Global Heart. E.S.-T. has received speaker honoraria from Sanofi, Novartis, Sobi, and Daiichi Sankyo. She has participated in trials run by Novartis and Amgen and is participating in KASCADE Lp(a). G.F.W. is a consultant for Amgen, Arrowhead, Esperion, CSL Sequirus, Novartis, and Novo Nordisk. He has received speaker honoraria from Arrowhead, Amgen, CSL Sequirus, Novartis, and Novo Nordisk. He is involved in clinical trials run by Amgen and Arrowhead and participates in research funded by Novartis. He has received travel grants from Arrowhead, Novo Nordisk, and Amgen. A.W. has received speaker and/or consultant fees from Algorithm, Chiesi, Merck, Novartis, Sanofi, Silence Therapeutics, and Ultragenyx and research grants from Amgen, Sanofi/Regeneron, Novartis, Silence Therapeutics, Esperion, and Ultragenyx. Fees and research grants received are used to support the running of his research institute. He is secretary of the board of FH Europe Foundation. M.Benn, L.C.H., and R.P. do not have any existing or known future financial relationships or commercial affiliations to the health industry to disclose.

Data Availability

No data were generated or analysed for or in support of this paper.

Funding

We acknowledge Chiesi Farmaceutici, Sanofi-Aventis Groupe, and Ultragenyx Europe for their support through unrestricted educational grants to the European Atherosclerosis Society.

Appendix

Young EAS Fellows actively involved in the review process are as follows: Roberto Scicali, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Tatyana Storozhenko, Cardiovascular Center Aalst, Aalst, Belgium, and Department of Prevention and Treatment of Emergency Conditions, L.T. Malaya Therapy National Institute NAMSU, Kharkiv, Ukraine.

CEO of patient organization actively involved in the review process: FH Europe Foundation: Magdalena Daccord.

Presidents of National Societies actively involved in the review process are as follows: Argentina: Argentina Lipid Society, Pablo Corral; Australia: Australian Atherosclerosis Society, Judy de Haan; Austria: Austrian Atherosclerosis Society, Florian Kronenberg; Bosnia and Herzegovina: Association of Cardiologists in Bosnia and Herzegovina, Sekib Sokolovic; Croatia: Croatian Medical Association, Croatian Society for Atherosclerosis, Zeljko Reiner; Cyprus: Cyprus

Atherosclerosis Society, Phivos Symeonides; Czech Republic: Czech Society for Atherosclerosis, Michal Vrablik; Finland: Finnish Atherosclerosis Society, Pirkka-Pekka Laurila; France: New French Society of Atherosclerosis (NSFA), René Valero; Georgia: Georgian Atherosclerosis Association, Tea Gamezardashvili; Germany: DACH Society for the Prevention of Heart and Circulatory Diseases, Ioanna Gouni-Berthold; Greece: Atherosclerosis Society of Northern Greece, Christodoulos Papadopoulos; Greece: Hellenic Atherosclerosis Society, Demosthenis Panagiotakos; Iraq: The Iraqi Lipid Clinics Network, Mutaz Al-Khnifawi; Ireland: Irish Lipid Network, Ian Menown; Israel: Medical Association- Society for Research, Prevention and Treatment of Atherosclerosis, Dov Gavish; Kyrgyzstan: Kyrgyz Atherosclerosis Society, Erkin Mirrakhimov; Latvia: Latvian Society of Hypertension and Atherosclerosis, Karlis Trusinskis; Mexico: Mexican Society of Atherosclerosis-AMPAC, Juan José Parceró Valdés; Russia: Russian National Atherosclerosis Society, Marat Ezhov; Spain: Spanish Society of Arteriosclerosis, Carlos Guijarro; Turkey: Turkish Society of Cardiology, Baris Gungor; Ukraine: Ukrainian Atherosclerosis Society, Olena Mitchenko; Uzbekistan: Atherosclerosis Society of Uzbekistan (ASU), Alexander B. Shek.

References

- Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia. *J Am Coll Cardiol* 2020;**75**:2553–66. <https://doi.org/10.1016/j.jacc.2020.03.057>
- Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. *Circulation* 2020;**141**:1742–59. <https://doi.org/10.1161/CIRCULATIONAHA.119.044795>
- Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society consensus panel. *Eur Heart J* 2017;**38**:2459–72. <https://doi.org/10.1093/eurheartj/ehx144>
- Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur Heart J* 2015;**36**:2425–37. <https://doi.org/10.1093/eurheartj/ehv157>
- Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Aversa M, et al. 2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. *Eur Heart J* 2023;**44**:2277–91. <https://doi.org/10.1093/eurheartj/ehad197>
- Dharmayat KI, Vallejo-Vaz AJ, Stevens CAT, Brandts JM, Lyons ARM, Groselj U, et al. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. *Lancet* 2024;**403**:55–66. [https://doi.org/10.1016/S0140-6736\(23\)01842-1](https://doi.org/10.1016/S0140-6736(23)01842-1)
- Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, Dharmayat KI, Freiburger T, Hovingh GK, et al. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet* 2021;**398**:1713–25. [https://doi.org/10.1016/S0140-6736\(21\)01122-3](https://doi.org/10.1016/S0140-6736(21)01122-3)
- Groselj U, Wiegman A, Gidding SS. Screening in children for familial hypercholesterolaemia: start now. *Eur Heart J* 2022;**43**:3209–12. <https://doi.org/10.1093/eurheartj/ehac224>
- Bytyci I, Bytyqi S, Lewek J, Surma S, Bajraktari G, Henein M, et al. Management of children with heterozygous familial hypercholesterolaemia worldwide: a meta-analysis. *Eur Heart J Open* 2025;**5**:oeaf001. <https://doi.org/10.1093/ehjopen/oeaf001>
- Van Bergen En Henegouwen K, Hutten BA, Lurink IK, Wiegman A, De Groot E, Kusters DM. Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: a systematic review and meta-analysis. *J Clin Lipidol* 2022;**16**:128–42. <https://doi.org/10.1016/j.jacl.2022.01.009>

11. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. *Lancet* 2004;**363**:369–70. [https://doi.org/10.1016/S0140-6736\(04\)15467-6](https://doi.org/10.1016/S0140-6736(04)15467-6)
12. Kusters DM, Wiegman A, Kastelein JJP, Hutten BA. Carotid intima-media thickness in children with familial hypercholesterolemia. *Circ Res* 2014;**114**:307–10. <https://doi.org/10.1161/CIRCRESAHA.114.301430>
13. De Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJP, Stroes ESG. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. *Atherosclerosis* 2002;**163**:193–7. [https://doi.org/10.1016/S0021-9150\(02\)00003-5](https://doi.org/10.1016/S0021-9150(02)00003-5)
14. Schmieder RS, Krefting J, Ates S, Schlieben LD, Arens S, Kordonouri O, et al. Clinical scores fail to sufficiently identify children with familial hypercholesterolemia. *Eur J Prev Cardiol* 2025;**33**:361–9. <https://doi.org/10.1093/eurjpc/zwaf301>
15. Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. *Eur Heart J* 2025;**46**:4359–78. <https://doi.org/10.1093/eurheartj/ehaf190>
16. Coerkamp CF, Verpalen VA, Bouhoubou K, Renkens MPL, Witte LS, Kaiser Y, et al. Lipoprotein(a) and the early diagnosis, complexity, and extent of coronary artery disease and myocardial infarction. *JACC Adv* 2026;**5**:102542. <https://doi.org/10.1016/j.jaccadv.2025.102542>
17. Starr B, Hadfield SG, Hutten BA, Lansberg PJ, Leren TP, Damgaard D, et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. *Clin Chem Lab Med* 2008;**46**:791–803. <https://doi.org/10.1515/CCLM.2008.135>
18. Hedegaard BS, Nordestgaard BG, Kanstrup HL, Thomsen KK, Bech J, Bang LE, et al. High lipoprotein(a) may explain one-quarter of clinical familial hypercholesterolemia diagnoses in Danish lipid clinics. *J Clin Endocrinol Metab* 2024;**109**:659–67. <https://doi.org/10.1210/clinem/dgag625>
19. De Boer LM, Hutten BA, Zwinderman AH, Wiegman A. Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study. *Eur Heart J* 2023;**44**:1421–8. <https://doi.org/10.1093/eurheartj/ehac660>
20. Arsenaault BJ, Kamstrup PR. Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective. *Atherosclerosis* 2022;**349**:7–16. <https://doi.org/10.1016/j.atherosclerosis.2022.04.015>
21. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. *BMJ* 1991;**303**:893–6. <https://doi.org/10.1136/bmj.303.6807.893>
22. Defesche J, Lansberg P, Umans-Eckenhausen M, Kastelein J. Advanced method for the identification of patients with inherited hypercholesterolemia. *Semin Vasc Med* 2004;**4**:59–65. <https://doi.org/10.1055/s-2004-822987>
23. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. *Am J Cardiol* 1993;**72**:171–6. [https://doi.org/10.1016/0002-9149\(93\)90155-6](https://doi.org/10.1016/0002-9149(93)90155-6)
24. Kafol J, Miranda B, Sikonja R, Sikonja J, Wiegman A, Medeiros AM, et al. Proposal of a familial hypercholesterolemia paediatric diagnostic score (FH-PeDS). *Eur J Prev Cardiol* 2025:zwaf352. <https://doi.org/10.1093/eurjpc/zwaf352>
25. Bittner V. Screening for familial hypercholesterolaemia: children are not small adults. *Eur J Prev Cardiol* 2025:zwaf565. <https://doi.org/10.1093/eurjpc/zwaf565>
26. Brown EE, Sturm AC, Cuchel M, Braun LT, Duell PB, Underberg JA, et al. Genetic testing in dyslipidemia: a scientific statement from the National Lipid Association. *J Clin Lipidol* 2020;**14**:398–413. <https://doi.org/10.1016/j.jacl.2020.04.011>
27. Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, et al. Clinical genetic testing for familial hypercholesterolemia. *J Am Coll Cardiol* 2018;**72**:662–80. <https://doi.org/10.1016/j.jacc.2018.05.044>
28. Chora JR, Iacocca MA, Tichý L, Wand H, Kurtz CL, Zimmermann H, et al. The Clinical Genome Resource (ClinGen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. *Genet Med* 2022;**24**:293–306. <https://doi.org/10.1016/j.gim.2021.09.012>
29. Civeira F, Martín C, Cenarro A. APOE and familial hypercholesterolemia. *Curr Opin Lipidol* 2024;**35**:195–9. <https://doi.org/10.1097/MOL.00000000000000937>
30. Othman RA, Myrie SB, Jones PJH. Non-cholesterol sterols and cholesterol metabolism in sitosterolemia. *Atherosclerosis* 2013;**231**:291–9. <https://doi.org/10.1016/j.atherosclerosis.2013.09.038>
31. Ramaswami U, Humphries SE. Inborn errors of lipoprotein metabolism presenting in childhood. In: Saudubray JM, Baumgartner MR, García-Cazorla Á, Walter J (eds.), *Inborn Metabolic Diseases: Diagnosis and Treatment*. Berlin, Germany: Springer-Verlag, 2022, 677–91.
32. Bredefeld C, Hussain MM, Aversa M, Black DD, Brin MF, Burnett JR, et al. Guidance for the diagnosis and treatment of hypolipidemia disorders. *J Clin Lipidol* 2022;**16**:797–812. <https://doi.org/10.1016/j.jacl.2022.08.009>
33. Blanco-Vaca F, Martín-Campos JM, Beteta-Vicente Á, Canyelles M, Martínez S, Roig R, et al. Molecular analysis of APOB, SAR1B, ANGPTL3, and MTP in patients with primary hypocholesterolemia in a clinical laboratory setting: evidence supporting polygenicity in mutation-negative patients. *Atherosclerosis* 2019;**283**:52–60. <https://doi.org/10.1016/j.atherosclerosis.2019.01.036>
34. Huijgen R, Sjouke B, Vis K, de Randamie JSE, Defesche JC, Kastelein JJP, et al. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-C levels. *Hum Mutat* 2012;**33**:448–55. <https://doi.org/10.1002/humu.21660>
35. Reijman MD, Defesche JC, Wiegman A. Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia. *Curr Opin Lipidol* 2023;**34**:287–95. <https://doi.org/10.1097/MOL.0000000000000863>
36. Keenan KF, Finnie RM, Simpson WG, McKee L, Dean J, Miedzybrodzka Z. Parents' views of genetic testing and treatment of familial hypercholesterolemia in children: a qualitative study. *J Community Genet* 2019;**10**:129–41. <https://doi.org/10.1007/s12687-018-0373-5>
37. Svendsen K, Langslet G, Krogh HW, Brinck J, Klausen IC, Stenehjem JS, et al. Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: examples from Scandinavia. *Atherosclerosis* 2021;**316**:48–52. <https://doi.org/10.1016/j.atherosclerosis.2020.11.027>
38. Constantin AT, Delia C, Roşu LM, Roşca I, Streaţă I, Riza AL, et al. The importance of genetic testing for familial hypercholesterolemia: a Pediatric Pilot Study. *Medicina* 2024;**60**:1602. <https://doi.org/10.3390/medicina60101602>
39. Peretti N, Vimont A, Mas E, Ferrières J, Tounian P, Lemale J, et al. Factors predicting statin initiation during childhood in familial hypercholesterolemia: importance of genetic diagnosis. *J Pediatr* 2023;**253**:18–24.e2. <https://doi.org/10.1016/j.jpeds.2022.08.041>
40. Lenin C, Lim PXH, Nastar A, Subramaniam T, Pek S, Daccord M, et al. Facilitators and barriers to uptake of genetic and cascade testing in familial hypercholesterolemia: a systematic review. *Int J Behav Med* 2026;**33**:69–82. <https://doi.org/10.1007/s12529-025-10357-y>
41. Lutzke JR, Ayers TS, Sandler IN, Barr A. Risks and interventions for the parentally bereaved child. In: Wolchik SA, Sandler IN (eds.), *Handbook of Children's Coping. Issues in Clinical Child Psychology*. New York, NY: Springer, 1997, 215–43.
42. Li J, Vestergaard M, Cnattingius S, Gissler M, Bech BH, Obel C, et al. Mortality after parental death in childhood: a nationwide cohort study from three Nordic countries. *PLoS Med* 2014;**11**:e1001679. <https://doi.org/10.1371/journal.pmed.1001679>
43. Futema M, Shah S, Cooper JA, Li K, Whittall RA, Sharifi M, et al. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. *Clin Chem* 2015;**61**:231–8. <https://doi.org/10.1373/clinchem.2014.231365>
44. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. *Lancet* 2013;**381**:1293–301. [https://doi.org/10.1016/S0140-6736\(12\)62127-8](https://doi.org/10.1016/S0140-6736(12)62127-8)
45. Futema M, Bourbon M, Williams M, Humphries SE. Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia. *Atherosclerosis* 2018;**277**:457–63. <https://doi.org/10.1016/j.atherosclerosis.2018.06.006>
46. Campbell-Salome G, Walters NL, Ladd IG, Sheldon A, Ahmed CD, Brangan A, et al. Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication. *Transl Behav Med* 2022;**12**:800–9. <https://doi.org/10.1093/tbm/ibac018>
47. Cardiovascular health—Public Health—European Commission. January 26, 2026. https://health.ec.europa.eu/non-communicable-diseases/cardiovascular-health_en (31 January 2026, date last accessed).
48. Singer MR, Moore LL, Garrahe EJ, Ellison RC. The tracking of nutrient intake in young children: the Framingham Children's Study. *Am J Public Health* 1995;**85**:1673–7. <https://doi.org/10.2105/AJPH.85.12.1673>
49. Patrick H, Nicklas TA. A review of family and social determinants of children's eating patterns and diet quality. *J Am Coll Nutr* 2005;**24**:83–92. <https://doi.org/10.1080/07315724.2005.10719448>
50. Pakkala K, Laitinen TT, Niinikoski H, Kartiosuo N, Rovio SP, Lagström H, et al. Effects of 20-year infancy-onset dietary counselling on cardiometabolic risk

- factors in the Special Turku Coronary Risk Factor Intervention Project (STRIP): 6-year post-intervention follow-up. *Lancet Child Adolesc Health* 2020;**4**:359–69. [https://doi.org/10.1016/S2352-4642\(20\)30059-6](https://doi.org/10.1016/S2352-4642(20)30059-6)
51. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. *BMJ* 2007;**335**:599. <https://doi.org/10.1136/bmj.39300.616076.55>
 52. Zuurbier LC, Defesche JC, Wiegman A. Successful genetic screening and creating awareness of familial hypercholesterolemia and other heritable dyslipidemias in The Netherlands. *Genes (Basel)* 2021;**12**:1168. <https://doi.org/10.3390/genes12081168>
 53. Vrablík M, Václavová M, Tichý L, Soška V, Bláha V, Fajkusová L, et al. Familial hypercholesterolemia in the Czech republic: more than 17 years of systematic screening within the MedPed project. *Physiol Res* 2017;**66**:S1–9. <https://doi.org/10.33549/physiolres.933600>
 54. Sustar U, Kordonouri O, Mlinaric M, Kovac J, Arens S, Sedej K, et al. Universal screening for familial hypercholesterolemia in 2 populations. *Genet Med* 2022;**24**:2103–11. <https://doi.org/10.1016/j.gim.2022.06.010>
 55. Gidding SS, Wiegman A, Grosej U, Freiburger T, Peretti N, Dharmayat KI, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. *Eur J Prev Cardiol* 2022;**29**:2301–11. <https://doi.org/10.1093/eurjpc/zwac200>
 56. Ademi Z, Norman R, Pang J, Sijbrands E, Watts GF, Hutten BA, et al. Cost-effectiveness and return on investment of a nationwide case-finding program for familial hypercholesterolemia in children in The Netherlands. *JAMA Pediatr* 2023;**177**:625. <https://doi.org/10.1001/jamapediatrics.2023.0763>
 57. Leren TP, Bogsrud MP. The importance of cascade genetic screening for diagnosing autosomal dominant hypercholesterolemia: results from twenty years of a national screening program in Norway. *J Clin Lipidol* 2021;**15**:674–81. <https://doi.org/10.1016/j.jacl.2021.08.007>
 58. Grosej U, Kovac J, Sustar U, Mlinaric M, Fras Z, Podkrajsek KT, et al. Universal screening for familial hypercholesterolemia in children: the Slovenian model and literature review. *Atherosclerosis* 2018;**277**:383–91. <https://doi.org/10.1016/j.atherosclerosis.2018.06.858>
 59. Klančar G, Grosej U, Kovač J, Bratanič N, Bratina N, Trebušak Podkrajšek K, et al. Universal screening for Familial Hypercholesterolemia in Children. *J Am Coll Cardiol* 2015;**66**:1250–7. <https://doi.org/10.1016/j.jacc.2015.07.017>
 60. Sanin V, Schmieder R, Ates S, Schlieben LD, Wiehler J, Sun R, et al. Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. *Eur J Public Health* 2022;**32**:422–8. <https://doi.org/10.1093/eurpub/ckac007>
 61. McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1–2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost-utility analysis. *Atherosclerosis* 2018;**275**:434–43. <https://doi.org/10.1016/j.atherosclerosis.2018.05.047>
 62. Araujo MB, Zerbino MC. Cost-effectiveness of pediatric universal screening for familial hypercholesterolemia in Argentina. *Value Health Reg Issues* 2023;**33**:33–41. <https://doi.org/10.1016/j.vhri.2022.08.009>
 63. Bellows BK, Zhang Y, Ruiz-Negrón N, Kazi DS, Khara AV, Woo JG, et al. Familial hypercholesterolemia screening in childhood and early adulthood: a cost-effectiveness study. *JAMA* 2026;**335**:140–53. <https://doi.org/10.1001/jama.2025.20648>
 64. Casula M, Gazzotti M, Capra ME, Olmastroni E, Galimberti F, Catapano AL, et al. Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: evidence from the LIPIGEN study. *Atherosclerosis* 2023;**385**:117231. <https://doi.org/10.1016/j.atherosclerosis.2023.117231>
 65. Pederiva C, Galimberti F, Casula M, Banderali G, Beccuti G, Bianconi V, et al. Diagnosis and screening strategies for detection of familial hypercholesterolaemia in children and adolescents in Italy: a survey from the LIPIGEN Paediatric Group. *Child Basel Switz* 2025;**12**:288. <https://doi.org/10.3390/children12030288>
 66. Medeiros AM, Alves AC, Bourbon M. Mutational analysis of a cohort with clinical diagnosis of familial hypercholesterolemia: considerations for genetic diagnosis improvement. *Genet Med* 2016;**18**:316–24. <https://doi.org/10.1038/gim.2015.71>
 67. Wald DS, Bestwick JP, Morris JK, Whyte K, Jenkins L, Wald NJ. Child–parent familial hypercholesterolemia screening in primary care. *N Engl J Med* 2016;**375**:1628–37. <https://doi.org/10.1056/NEJMoa1602777>
 68. Cox E, Faria R, Saramago P, Haralambos K, Watson M, Humphries SE, et al. Challenges and opportunities for identifying people with familial hypercholesterolemia in the UK: evidence from the National FH PASS database. *J Clin Lipidol* 2024;**18**:e1046–54. <https://doi.org/10.1016/j.jacl.2024.08.007>
 69. Santos RD, Gidding SS, Bourbon M, Iatan I, Harada-Shiba M, Raal FJ, et al. Recent advances in research and care of familial hypercholesterolaemia. *Lancet Diabetes Endocrinol* 2025;**13**:1054–71. [https://doi.org/10.1016/S2213-8587\(25\)00286-4](https://doi.org/10.1016/S2213-8587(25)00286-4)
 70. Bedlington N, Abifadel M, Beger B, Bourbon M, Bueno H, Ceska R, et al. The time is now: achieving FH paediatric screening across Europe—the Prague Declaration. *GMS Health Innov Technol* 2022;**16**:Doc04. <https://doi.org/10.3205/HTA000136>
 71. Ceska R, Latkovskis G, Ezhov MV, Freiburger T, Lalic K, Mitchenko O, et al. The impact of the international cooperation on familial hypercholesterolemia screening and treatment: results from the ScreenPro FH Project. *Curr Atheroscler Rep* 2019;**21**:36. <https://doi.org/10.1007/s11883-019-0797-3>
 72. Loeber JG, Platis D, Zetterström RH, Almashanu S, Boemer F, Bonham JR, et al. Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010. *Int J Neonatal Screen* 2021;**7**:15. <https://doi.org/10.3390/ijns7010015>
 73. Held PK, Lasarev M, Zhang X, Wiberley-Bradford AE, Campbell K, Horner V, et al. Familial hypercholesterolemia biomarker distribution in dried blood spots. *J Pediatr* 2023;**259**:113469. <https://doi.org/10.1016/j.jpeds.2023.113469>
 74. Loeber JW, Campbell K, Wiberley-Bradford AE, Lasarev M, Horner V, Peterson A. Analytical validation of familial hypercholesterolemia biomarkers in dried blood spots. *Int J Neonatal Screen* 2022;**8**:14. <https://doi.org/10.3390/ijns8010014>
 75. Flyer JN, Freiburger T, Ware AL, Peterson AL. State-of-the-art review: the value of leveraging evidence and data (LEAD) in pediatric screening for familial hypercholesterolemia. *Am J Prev Cardiol* 2025;**23**:101262. <https://doi.org/10.1016/j.ajpc.2025.101262>
 76. Peterson AL, Horner V, Lasarev MR, Zhang X, Humphries SE, Steiner RD, et al. Genetic diagnosis of familial hypercholesterolemia in residual newborn dried blood spots. *JAMA Cardiol* 2025;**10**:1315–9. <https://doi.org/10.1001/jamacardio.2025.4047>
 77. Balder JW, Lansberg PJ, Hof MH, Wiegman A, Hutten BA, Kuivenhoven JA. Pediatric lipid reference values in the general population: the Dutch lifelines cohort study. *J Clin Lipidol* 2018;**12**:1208–16. <https://doi.org/10.1016/j.jacl.2018.05.011>
 78. Øyri LKL, Bogsrud MP, Christensen JJ, Ulven SM, Brantsæter AL, Retterstøl K, et al. Novel associations between parental and newborn cord blood metabolic profiles in the Norwegian mother, father and child cohort study. *BMC Med* 2021;**19**:91. <https://doi.org/10.1186/s12916-021-01959-w>
 79. Taageby Nielsen S, Mohr Lytsen R, Strandkjær N, Juul Rasmussen I, Sillesen AS, Vøgg ROB, et al. Significance of lipids, lipoproteins, and apolipoproteins during the first 14–16 months of life. *Eur Heart J* 2023;**44**:4408–18. <https://doi.org/10.1093/eurheartj/ehad547>
 80. Bogsrud MP, Stava TT, Berge KE, Strøm TB, Retterstøl K, Holven KB. LDL-cholesterol in newborns and children with genetically verified familial hypercholesterolaemia: implications for cholesterol-based screening. *Eur Heart J* 2025;**46**:5261–9. <https://doi.org/10.1093/eurheartj/ehaf815>
 81. Zhou Y, Luo G, Zhang A, Gao S, Tang Y, Du Z, et al. Genetic identification of familial hypercholesterolemia within whole genome sequences in 6820 newborns. *Clin Genet* 2024;**105**:308–12. <https://doi.org/10.1111/cge.14453>
 82. Ibrahim S, Reeskamp LF, de Goeij JN, Hovingh GK, Planken RN, Bax WA, et al. Beyond early LDL cholesterol lowering to prevent coronary atherosclerosis in familial hypercholesterolaemia. *Eur J Prev Cardiol* 2024;**31**:892–900. <https://doi.org/10.1093/eurjpc/zwae028>
 83. Zhang Y, Pletcher MJ, Vittinghoff E, Clemons AM, Jacobs DR, Allen NB, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. *JAMA Cardiol* 2021;**6**:1406. <https://doi.org/10.1001/jamacardio.2021.3508>
 84. Cheng KS, Mikhailidis DP, Hamilton G, Seifalian AM. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. *Cardiovasc Res* 2002;**54**:528–38. [https://doi.org/10.1016/s0008-6363\(01\)00551-x](https://doi.org/10.1016/s0008-6363(01)00551-x)
 85. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. *JAMA* 2004;**292**:331–7. <https://doi.org/10.1001/jama.292.3.331>
 86. Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, et al. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). *Circulation* 2017;**136**:359–66. <https://doi.org/10.1161/CIRCULATIONAHA.116.025158>
 87. Lührink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, De Groot E, et al. 20-Year Follow-up of statins in children with familial hypercholesterolemia. *N Engl J Med* 2019;**381**:1547–56. <https://doi.org/10.1056/NEJMoa1816454>
 88. Wiegman A, Ruzza A, Hovingh GK, Santos RD, Mach F, Stefanutti C, et al. Evolocumab treatment reduces carotid intima-media thickness in paediatric

- patients with heterozygous familial hypercholesterolaemia. *Eur J Prev Cardiol* 2024;zwae369. <https://doi.org/10.1093/eurjpc/zwae369>
89. Schonck WAM, Reijman MD, Wiegman A, Ibrahim S, Corpeleijn WE, Planken RN, et al. Decreased LDL-cholesterol exposure following ANGPTL3 inhibition reduces coronary plaque development in homozygous familial hypercholesterolemia. *JACC Cardiovasc Imaging* 2024;17:1258–60. <https://doi.org/10.1016/j.jcmg.2024.05.005>
 90. Carmona C, Crutwell J, Burnham M, Polak L. Shared decision-making: summary of NICE guidance. *BMJ* 2021;373:n1430. <https://doi.org/10.1136/bmj.n1430>
 91. Greene BL, Rosenberg AR, Marron JM. A communication and decision-making framework for pediatric precision medicine. *Pediatrics* 2024;153:e2023062850. <https://doi.org/10.1542/peds.2023-062850>
 92. Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. *Nat Rev Cardiol* 2023;20:845–69. <https://doi.org/10.1038/s41569-023-00892-0>
 93. Vuorio A, Docherty KF, Humphries SE, Kuoppala J, Kovanen PT. Statin treatment of children with familial hypercholesterolemia—trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? *Atherosclerosis* 2013;226:315–20. <https://doi.org/10.1016/j.atherosclerosis.2012.10.032>
 94. Reijman MD, Tromp TR, Hutten BA, Hovingh GK, Blom DJ, Catapano AL, et al. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. *Lancet Child Adolesc Health* 2024;8:491–9. [https://doi.org/10.1016/S2352-4642\(24\)00073-7](https://doi.org/10.1016/S2352-4642(24)00073-7)
 95. Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. *Lancet* 2022;399:719–28. [https://doi.org/10.1016/S0140-6736\(21\)02001-8](https://doi.org/10.1016/S0140-6736(21)02001-8)
 96. McMahan CA. Risk scores predict atherosclerotic lesions in young people. *Arch Intern Med* 2005;165:883. <https://doi.org/10.1001/archinte.165.8.883>
 97. Coassin S, Kronenberg F. Lipoprotein(a) beyond the krigle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. *Atherosclerosis* 2022;349:17–35. <https://doi.org/10.1016/j.atherosclerosis.2022.04.003>
 98. Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, et al. Lepodisiran — a long-duration small interfering RNA targeting lipoprotein(a). *N Engl J Med* 2025;392:1673–83. <https://doi.org/10.1056/NEJMoa2415818>
 99. Raitakari O, Kartiosuo N, Pahlkala K, Hutri-Kähönen N, Bazzano LA, Chen W, et al. Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood. *Circulation* 2023;147:23–31. <https://doi.org/10.1161/CIRCULATIONAHA.122.060667>
 100. Paquette M, Baass A. Predicting cardiovascular disease in familial hypercholesterolemia. *Curr Opin Lipidol* 2018;29:299–306. <https://doi.org/10.1097/mol.0000000000000519>
 101. de Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. *Circulation* 2019;139:e603–34. <https://doi.org/10.1161/CIR.0000000000000618>
 102. Sharma A, Gupta I, Venkatesh U, Singh AK, Golamari R, Arya P. E-cigarettes and myocardial infarction: a systematic review and meta-analysis. *Int J Cardiol* 2023;371:65–70. <https://doi.org/10.1016/j.ijcard.2022.09.007>
 103. Yacoub MI, Aslanoglu A, Khraim F, Alsharawneh A, Abdelkader R, Almagharbeh WT, et al. Comparing E-cigarettes and traditional cigarettes in relation to myocardial infarction, arrhythmias, and sudden cardiac death: a systematic review and meta-analysis. *Biol Res Nurs* 2025;27:168–85. <https://doi.org/10.1177/10998004241287782>
 104. Pérez De Isla L, Alonso R, Gómez De Diego JJ, Muñoz-Grijalvo O, Díaz-Díaz JL, Zambón D, et al. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: a computed tomographic angiography study. *Atherosclerosis* 2021;317:52–8. <https://doi.org/10.1016/j.atherosclerosis.2020.11.012>
 105. Miname MH, Bittencourt MS, Moraes SR, Alves RIM, Silva PRS, Jannes CE, et al. Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy. *JACC Cardiovasc Imaging* 2019;12:1797–804. <https://doi.org/10.1016/j.jcmg.2018.09.019>
 106. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American society of echocardiography carotid intima-media thickness task force endorsed by the Society for Vascular Medicine. *J Am Soc Echocardiogr* 2008;21:93–111. <https://doi.org/10.1016/j.echo.2007.11.011>
 107. Reijman MD, Van Den Bosch SE, Kusters DM, Corpeleijn WE, Hutten BA, Kuipers IM, et al. CTCA in children with severe heterozygous familial hypercholesterolaemia: screening for subclinical atherosclerosis. *Atheroscler Plus* 2024;55:1–4. <https://doi.org/10.1016/j.athplu.2023.12.002>
 108. EXPERT PANEL ON INTEGRATED GUIDELINES FOR CARDIOVASCULAR HEALTH AND RISK REDUCTION IN CHILDREN AND ADOLESCENTS. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics* 2011;128:S213–56. <https://doi.org/10.1542/peds.2009-2107C>
 109. Bechthold A, Boeing H, Schwedhelm C, Hoffmann G, Knüppel S, Iqbal K, et al. Food groups and risk of coronary heart disease, stroke and heart failure: a systematic review and dose-response meta-analysis of prospective studies. *Crit Rev Food Sci Nutr* 2019;59:1071–90. <https://doi.org/10.1080/10408398.2017.1392288>
 110. Rodríguez-Borjabad C, Narveud I, Christensen JJ, Ulven SM, Malo AI, Ibarretxe D, et al. Dietary intake and lipid levels in Norwegian and Spanish children with familial hypercholesterolemia. *Nutr Metab Cardiovasc Dis* 2021;31:1299–307. <https://doi.org/10.1016/j.numecd.2020.12.002>
 111. Griffin JD, Lichtenstein AH. Dietary cholesterol and plasma lipoprotein profiles: randomized controlled trials. *Curr Nutr Rep* 2013;2:274–82. <https://doi.org/10.1007/s13668-013-0064-0>
 112. Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. *Am J Clin Nutr* 2015;102:276–94. <https://doi.org/10.3945/ajcn.114.100305>
 113. Christensen JJ, Arnesen EK, Rundblad A, Telle-Hansen VH, Narverud I, Blomhoff R, et al. Dietary fat quality, plasma atherogenic lipoproteins, and atherosclerotic cardiovascular disease: an overview of the rationale for dietary recommendations for fat intake. *Atherosclerosis* 2024;389:117433. <https://doi.org/10.1016/j.atherosclerosis.2023.117433>
 114. Gidding SS, Dennison BA, Birch LL, Daniels SR, Gilman MW, Lichtenstein AH, et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. *Circulation* 2005;112:2061–75. <https://doi.org/10.1161/CIRCULATIONAHA.105.169251>
 115. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J* 2020;41:111–88. <https://doi.org/10.1093/eurheartj/ehz455>
 116. Maki KC, Dicklin MR, Kirkpatrick CF. Saturated fats and cardiovascular health: current evidence and controversies. *J Clin Lipidol* 2021;15:765–72. <https://doi.org/10.1016/j.jacl.2021.09.049>
 117. Kelishadi R, Mansourian M, Heidari-Beni M. Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. *Nutrition* 2014;30:503–10. <https://doi.org/10.1016/j.nut.2013.08.014>
 118. AVIS révisé de l'Anses relatif à l'actualisation des repères alimentaires du PNNS—Enfants (4 à 17 ans). Anses—Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail. December 23, 2019. <https://www.anses.fr/fr/content/avis-reviser-de-lanses-relatif-lactualisation-des-reperes-alimentaires-du-pnns-enfants-4-17> (1 June 2025, date last accessed).
 119. Hallström L, Labayen I, Ruiz JR, Patterson E, Vereecken CA, Breidenassel C, et al. Breakfast consumption and CVD risk factors in European adolescents: the HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) study. *Public Health Nutr* 2013;16:1296–305. <https://doi.org/10.1017/S1368980012000973>
 120. Cayres SU, Júnior IFF, Barbosa MF, Christofaro DGD, Fernandes RA. Breakfast frequency, adiposity, and cardiovascular risk factors as markers in adolescents. *Cardiol Young* 2016;26:244–9. <https://doi.org/10.1017/S1047951115000050>
 121. Obarzane E, Kimm SYS, Barton BA, Van Horn L, Kwiterovich PO, Simons-Morton DG, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). *Pediatrics* 2001;107:256–64. <https://doi.org/10.1542/peds.107.2.256>
 122. Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association nutrition subcommittee of the council on nutrition, physical activity, and metabolism; council on cardiovascular nursing; and council on epidemiology and prevention. *Circulation* 2009;119:902–7. <https://doi.org/10.1161/CIRCULATIONAHA.108.191627>
 123. Blomhoff R, Andersen R, Arnesen EK, Christensen JJ, Eneroth H, Erkkola M, et al. Nordic Nutrition Recommendations 2023. Copenhagen: Nordic Council of Ministers, 2023. <https://doi.org/10.6027/nord2023-003>

124. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999;**99**:779–85. <https://doi.org/10.1161/01.CIR.99.6.779>
125. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA). Scientific opinion on dietary reference values for carbohydrates and dietary fibre. *EFSA J* 2010;**8**:1462. <https://doi.org/10.2903/j.efsa.2010.1462>
126. Niinikoski H, Lagström H, Jokinen E, Siltala M, Rönnemaa T, Viikari J, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and Serum lipids and lipoproteins. *Circulation* 2007;**116**:1032–40. <https://doi.org/10.1161/CIRCULATIONAHA.107.699447>
127. Barkas F, Nomikos T, Liberopoulos E, Panagiotakos D. Diet and cardiovascular disease risk among individuals with familial hypercholesterolemia: systematic review and meta-analysis. *Nutrients* 2020;**12**:2436. <https://doi.org/10.3390/nu12082436>
128. Vuorio A, Kovanen PT. Decreasing the cholesterol burden in heterozygous familial hypercholesterolemia children by dietary plant stanol esters. *Nutrients* 2018;**10**:1842. <https://doi.org/10.3390/nu10121842>
129. Jakulj L, Vissers MN, Rodenburg J, Wiegman A, Trip MD, Kastelein JJP. Plant stanols do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. *J Pediatr* 2006;**148**:495–500. <https://doi.org/10.1016/j.jpeds.2005.11.023>
130. Malhotra A, Shafiq N, Arora A, Singh M, Kumar R, Malhotra S. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. *Cochrane Database Syst Rev* 2014;**2014**:CD001918. <https://doi.org/10.1002/14651858.CD001918.pub3>
131. Molven I, Retterstøl K, Andersen LF, Veierød MB, Narverud I, Ose L, et al. Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children. *J Nutr Sci* 2013;**2**:e32. <https://doi.org/10.1017/jns.2013.27>
132. Torvik K, Narverud I, Ottstad I, Svilaas A, Gran JM, Retterstøl K, et al. Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia. *Atherosclerosis* 2016;**252**:21–7. <https://doi.org/10.1016/j.atherosclerosis.2016.07.913>
133. Lichtenstein AH, Appel LJ, Vadiveloo M, Hu FB, Kris-Etherton PM, Rebholz CM, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. *Circulation* 2021;**144**:e472–87. <https://doi.org/10.1161/CIR.0000000000001031>
134. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr* 2003;**77**:1146–55. <https://doi.org/10.1093/ajcn/77.5.1146>
135. Ferrari F, Martins VM, Rocha VZ, Santos RD. Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia. *Expert Opin Pharmacother* 2021;**22**:483–95. <https://doi.org/10.1080/14656566.2020.1832991>
136. Braamskamp MJAM, Stefanutti C, Langslet G, Drogari E, Wiegman A, Hounslow N, et al. Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. *J Pediatr* 2015;**167**:338–43.e5. <https://doi.org/10.1016/j.jpeds.2015.05.006>
137. Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study. *J Clin Lipidol* 2015;**9**:741–50. <https://doi.org/10.1016/j.jacl.2015.07.011>
138. Stein EA, Dann EJ, Wiegman A, Skovby F, Gaudet D, Sokal E, et al. Efficacy of rosuvastatin in children with homozygous familial hypercholesterolemia and association with underlying genetic mutations. *J Am Coll Cardiol* 2017;**70**:1162–70. <https://doi.org/10.1016/j.jacc.2017.06.058>
139. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. *J Pediatr* 2003;**143**:74–80. [https://doi.org/10.1016/S0022-3476\(03\)00186-0](https://doi.org/10.1016/S0022-3476(03)00186-0)
140. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. *Atherosclerosis* 2000;**150**:421–8. [https://doi.org/10.1016/S0021-9150\(99\)00435-9](https://doi.org/10.1016/S0021-9150(99)00435-9)
141. Van Der Graaf A, Nierman MC, Firth JC, Wolmarans KH, Marais AD, De Groot E. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. *Acta Paediatr* 2006;**95**:1461–6. <https://doi.org/10.1080/08035250600702602>
142. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. *JAMA* 1999;**281**:137. <https://doi.org/10.1001/jama.281.2.137>
143. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. *Pediatrics* 2005;**116**:682–8. <https://doi.org/10.1542/peds.2004-2090>
144. De Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. *Circulation* 2002;**106**:2231–7. <https://doi.org/10.1161/01.CIR.0000035247.42888.82>
145. Kusters DM, Caceres M, Coll M, Cuffie C, Gagné C, Jacobson MS, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. *J Pediatr* 2015;**166**:1377–84.e3. <https://doi.org/10.1016/j.jpeds.2015.02.043>
146. Van Der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. *J Am Coll Cardiol* 2008;**52**:1421–9. <https://doi.org/10.1016/j.jacc.2008.09.002>
147. Santos RD, Wiegman A, Caprio S, Cariou B, Aversa M, Poulouin Y, et al. Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial. *JAMA Pediatr* 2024;**178**:283. <https://doi.org/10.1001/jamapediatrics.2023.6477>
148. Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia. *N Engl J Med* 2020;**383**:1317–27. <https://doi.org/10.1056/NEJMoa2019910>
149. Santos RD, Ruzza A, Hovingh GK, Stefanutti C, Mach F, Descamps OS, et al. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. *Lancet Diabetes Endocrinol* 2022;**10**:732–40. [https://doi.org/10.1016/S2213-8587\(22\)00221-2](https://doi.org/10.1016/S2213-8587(22)00221-2)
150. Raal FJ, Hegele RA, Ruzza A, López JAG, Bhatia AK, Wu J, et al. Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies. *Arterioscler Thromb Vasc Biol* 2024;**44**:1156–64. <https://doi.org/10.1161/ATVBAHA.123.320268>
151. Wiegman A, Peterson AL, Bruckert E, Defesche JC, Schweizer A, Bergeron J, et al. Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial. *Lancet Diabetes Endocrinol* 2026;**14**:233–42. [https://doi.org/10.1016/S2213-8587\(25\)00351-1](https://doi.org/10.1016/S2213-8587(25)00351-1)
152. Wiegman A, Peterson AL, Hegele RA, Bruckert E, Schweizer A, Lesogor A, et al. Efficacy and safety of inclisiran in adolescents with genetically confirmed homozygous familial hypercholesterolemia: results from the double-blind, placebo-controlled part of the ORION-13 randomized trial. *Circulation* 2025;**151**:1758–66. <https://doi.org/10.1161/CIRCULATIONAHA.124.073233>
153. Stein EA, Marais AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. *J Pediatr* 2010;**156**:231–6.e3. <https://doi.org/10.1016/j.jpeds.2009.08.037>
154. Wiegman A, Greber-Platzter S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. *Circulation* 2024;**149**:343–53. <https://doi.org/10.1161/CIRCULATIONAHA.123.065529>
155. Masana L, Zambon A, Schmitt CP, Taylan C, Driemeyer J, Cohen H, et al. Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study. *Lancet Diabetes Endocrinol* 2024;**12**:880–9. [https://doi.org/10.1016/S2213-8587\(24\)00233-X](https://doi.org/10.1016/S2213-8587(24)00233-X)
156. Langslet G, Breazna A, Drogari E. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. *J Clin Lipidol* 2016;**10**:1153–62.e3. <https://doi.org/10.1016/j.jacl.2016.05.010>
157. Bogsrud MP, Langslet G, Wium C, Johansen D, Svilaas A, Holven KB. Treatment goal attainment in children with familial hypercholesterolemia: a cohort study of 302 children in Norway. *J Clin Lipidol* 2018;**12**:375–82. <https://doi.org/10.1016/j.jacl.2017.11.009>
158. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, et al. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev* 2019;**2019**:CD006401. <https://doi.org/10.1002/14651858.CD006401.pub5>
159. Dombalis S, Nash A. The effect of statins in children and adolescents with familial hypercholesterolemia: a systematic review. *J Pediatr Health Care* 2021;**35**:292–303. <https://doi.org/10.1016/j.pedhc.2020.11.007>
160. Mamann N, Lemale J, Karsenty A, Dubern B, Girardet JP, Tounian P. Intermediate-term efficacy and tolerance of statins in children. *J Pediatr* 2019;**210**:161–5. <https://doi.org/10.1016/j.jpeds.2019.03.032>

161. Kavey REW, Manhiot C, Runeckles K, Collins T, Gidding SS, Demczko M, et al. Effectiveness and safety of statin therapy in children: a real-world clinical practice experience. *CJC Open* 2020;**2**:473–82. <https://doi.org/10.1016/j.cjco.2020.06.002>
162. Braamskamp MJAM, Kusters DM, Avis HJ, Smets EMA, Wijburg FA, Kastelein JJP, et al. Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence. *Pediatr Drugs* 2015;**17**:159–66. <https://doi.org/10.1007/s40272-014-0116-y>
163. Braamskamp MJAM, Kusters DM, Wiegman A, Avis HJ, Wijburg FA, Kastelein JJP, et al. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood. *Atherosclerosis* 2015;**241**:427–32. <https://doi.org/10.1016/j.atherosclerosis.2015.05.034>
164. Kusters DM, Avis HJ, De Groot E, Wijburg FA, Kastelein JJP, Wiegman A, et al. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. *JAMA* 2014;**312**:1055. <https://doi.org/10.1001/jama.2014.8892>
165. Joyce NR, Zachariah JP, Eaton CB, Trivedi AN, Wellenius GA. Statin use and the risk of type 2 diabetes mellitus in children and adolescents. *Acad Pediatr* 2017;**17**:515–22. <https://doi.org/10.1016/j.acap.2017.02.006>
166. Van Den Bosch SE, Kowsolea FC, Corpeleijn WE, Huisman SA, Kowsolea AIE, Wiegman A, et al. Statin-associated symptoms and statin intolerance in children with familial hypercholesterolemia: insights from 15 years of clinical practice. *Atherosclerosis* 2026;**414**:120659. <https://doi.org/10.1016/j.atherosclerosis.2026.120659>
167. Desai NK, Mendelson MM, Baker A, Ryan HH, Griggs S, Boghani M, et al. Hepatotoxicity of statins as determined by serum alanine aminotransferase in a pediatric cohort with dyslipidemia. *J Pediatr Gastroenterol Nutr* 2019;**68**:175–81. <https://doi.org/10.1097/MPG.0000000000002174>
168. Johnson PK, Mendelson MM, Baker A, Ryan HH, Warren S, Graham D, et al. Statin-associated myopathy in a pediatric preventive cardiology practice. *J Pediatr* 2017;**185**:94–8.e1. <https://doi.org/10.1016/j.jpeds.2017.02.047>
169. Raal FJ, Mehta V, Kayikcioglu M, Blom D, Gupta P, Elis A, et al. Lerodalcibep and evolucumab for the treatment of homozygous familial hypercholesterolemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. *Lancet Diabetes Endocrinol* 2025;**13**:178–87. [https://doi.org/10.1016/S2213-8587\(24\)00313-9](https://doi.org/10.1016/S2213-8587(24)00313-9)
170. Johansen AK, Bogsrud MP, Christensen JJ, Rundblad A, Narverud I, Ulven S, et al. Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: novel data using repeated measurements during 12-years follow-up. *Atheroscler Plus* 2023;**51**:28–34. <https://doi.org/10.1016/j.athplu.2023.01.001>
171. Tarissi De Jacobis I, Straface E, Inzaghi E, Cittadini C, Bartoli M, Pagano MT, et al. Sex differences in lipid profile and response to statin treatment in pediatric patients affected by familial hypercholesterolemia. *Eur J Pediatr* 2025;**184**:571. <https://doi.org/10.1007/s00431-025-06397-x>
172. Klevmoen M, Bogsrud MP, Retterstøl K, Svilaas T, Vesterbekkmo EK, Hovland A, et al. Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. *Atherosclerosis* 2021;**335**:8–15. <https://doi.org/10.1016/j.atherosclerosis.2021.09.003>
173. Reith C, Baigent C, Blackwell L, Emberson J, Spata E, Davies K, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. *Lancet* 2022;**400**:832–45. [https://doi.org/10.1016/S0140-6736\(22\)01545-8](https://doi.org/10.1016/S0140-6736(22)01545-8)
174. Bays H, Cohen DE, Chalasani N, Harrison SA. An assessment by the statin liver safety task force: 2014 update. *J Clin Lipidol* 2014;**8**:S47–57. <https://doi.org/10.1016/j.jacl.2014.02.011>
175. Reith C, Preiss D, Blackwell L, Emberson J, Spata E, Davies K, et al. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. *Lancet Diabetes Endocrinol* 2024;**12**:306–19. [https://doi.org/10.1016/S2213-8587\(24\)00040-8](https://doi.org/10.1016/S2213-8587(24)00040-8)
176. Groselj U, Sikojka J, Mlinaric M, Kotnik P, Battelino T, Knowles JW. Analysis of insulin resistance among children and adolescents in Slovenia with hypercholesterolemia after treatment with statins. *JAMA Netw Open* 2022;**5**:e2231097. <https://doi.org/10.1001/jamanetworkopen.2022.31097>
177. Llewellyn A, Simmonds M, Marshall D, Harden M, Woods B, Humphries SE, et al. Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolemia: systematic review, pairwise and network meta-analyses of randomised controlled trials. *Atherosclerosis* 2025;**401**:118598. <https://doi.org/10.1016/j.atherosclerosis.2024.118598>
178. Santos RD, Ruzza A, Wang B, Maruff P, Schembri A, Bhatia AK, et al. Evolocumab in paediatric heterozygous familial hypercholesterolemia: cognitive function during 80 weeks of open-label extension treatment. *Eur J Prev Cardiol* 2024;**31**:302–10. <https://doi.org/10.1093/eurjpc/zwad332>
179. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. *Atherosclerosis* 2012;**223**:262–8. <https://doi.org/10.1016/j.atherosclerosis.2012.02.019>
180. Rallidis L, Nihoyannopoulos P, Thompson GR. Aortic stenosis in homozygous familial hypercholesterolemia. *Heart* 1996;**76**:84–5. <https://doi.org/10.1136/hrt.76.1.84>
181. Reijman MD, Kusters DM, Groothoff JW, Arbeiter K, Dann EJ, De Boer LM, et al. Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN. *Atherosclerosis* 2024;**392**:117525. <https://doi.org/10.1016/j.atherosclerosis.2024.117525>
182. Shiyovich A, Singh A, Blair CV, Cardoso R, Huck D, Peng G, et al. Photon-counting computed tomography in cardiac imaging. *JACC Cardiovasc Imaging* 2026;**19**:94–117. <https://doi.org/10.1016/j.jcmg.2025.07.022>
183. Pontone G, Mushtaq S, Pizzi C, Maurovich-Horvat P, Leipsic J, Serruys PW. Photon-counting computed tomography: a revolution in cardiac imaging. *Eur Heart J* 2026;ehaf1118. <https://doi.org/10.1093/eurheartj/ehaf1118>
184. Adam RC, Mintah IJ, Alexa-Braun CA, Shihanian LM, Lee JS, Banerjee P, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. *J Lipid Res* 2020;**61**:1271–86. <https://doi.org/10.1194/jlr.RA120000888>
185. Gaudet D, Greber-Platzer S, Reeskamp LF, Iannuzzo G, Rosenson RS, Saheb S, et al. Evinaucumab in homozygous familial hypercholesterolemia: long-term safety and efficacy. *Eur Heart J* 2024;**45**:2422–34. <https://doi.org/10.1093/eurheartj/ehae325>
186. Reeskamp LF, Nurmohamed NS, Bom MJ, Planken RN, Driessen RS, van Diemen PA, et al. Marked plaque regression in homozygous familial hypercholesterolemia. *Atherosclerosis* 2021;**327**:13–7. <https://doi.org/10.1016/j.atherosclerosis.2021.04.014>
187. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. *J Lipid Res* 2003;**44**:22–32. <https://doi.org/10.1194/jlr.R200014-JLR200>
188. Rader DJ, Kastelein JJP. Lomitapide and mipomersen. *Circulation* 2014;**129**:1022–32. <https://doi.org/10.1161/CIRCULATIONAHA.113.001292>
189. Luirink IK, Determeijer J, Hutten BA, Wiegman A, Bruckert E, Schmitt CP, et al. Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: a systematic review. *J Clin Lipidol* 2019;**13**:31–9. <https://doi.org/10.1016/j.jacl.2018.10.011>
190. Luirink IK, Hutten BA, Greber-Platzer S, Kolovou GD, Dann EJ, De Ferranti SD, et al. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: data from an international registry. *Atherosclerosis* 2020;**299**:24–31. <https://doi.org/10.1016/j.atherosclerosis.2020.01.031>
191. Ganos E, Duell PB, Toth PP, Moriarty PM, Thompson GR, Brinton EA, et al. Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Biol* 2024;**44**:e304–21. <https://doi.org/10.1161/ATV.000000000000177>
192. Stefanutti C, Pang J, Di Giacomo S, Wu X, Wang X, Morozzi C, et al. A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: the Sino-Roman study. *J Clin Lipidol* 2019;**13**:608–17. <https://doi.org/10.1016/j.jacl.2019.05.002>
193. Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. *Am J Cardiol* 2008;**102**:1199–204. <https://doi.org/10.1016/j.amjcard.2008.06.049>
194. Kroon AA, Van't Hof MA, Demacker PNM, Stalenhoef AFH. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. *Atherosclerosis* 2000;**152**:519–26. [https://doi.org/10.1016/S0021-9150\(00\)00371-3](https://doi.org/10.1016/S0021-9150(00)00371-3)
195. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL apheresis. *Atherosclerosis* 2010;**208**:317–21. <https://doi.org/10.1016/j.atherosclerosis.2009.06.010>
196. Thompson GR, Walji S, Cegla J. Liver transplantation for homozygous familial hypercholesterolemia. *Curr Opin Lipidol* 2025;**36**:310–7. <https://doi.org/10.1097/MOL.0000000000001007>
197. Salen G, von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. *Circulation* 2004;**109**:966–71. <https://doi.org/10.1161/01.CIR.0000116766.31036.03>
198. Burton BK, Balwani M, Feillet F, Barić I, Burrow TA, Camarena Grande C, et al. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. *N Engl J Med* 2015;**373**:1010–20. <https://doi.org/10.1056/NEJMoa1501365>
199. Ramaswami U, Humphries SE, Priestley-Barnham L, Green P, Wald DS, Capps N, et al. Current management of children and young people with heterozygous familial hypercholesterolemia—HEART UK statement of care. *Atherosclerosis* 2019;**290**:1–8. <https://doi.org/10.1016/j.atherosclerosis.2019.09.005>